var tipuesearch = {"pages": [{
    "title": "Demos",
    "text": "Demos Basic flowchart %% Example diagram graph LR A[Square Rect] -- Link text --&gt; B((Circle)) A --&gt; C(Round Rect) B --&gt; D{Rhombus} C --&gt; D graph LR A[Square Rect] -- Link text --&gt; B((Circle)) A --&gt; C(Round Rect) B --&gt; D{Rhombus} C --&gt; D Larger flowchart with some styling %% Code for flowchart below graph TB sq[Square shape] --&gt; ci((Circle shape)) subgraph A subgraph od&gt;Odd shape]-- Two line&amp;lt;br&gt;edge comment --&gt; ro di{Diamond with &amp;lt;br/&gt; line break} -.-&gt; ro(Rounded&amp;lt;br&gt;square&amp;lt;br&gt;shape) di==&gt;ro2(Rounded square shape) end %% Notice that no text in shape are added here instead that is appended further down e --&gt; od3&gt;Really long text with linebreak&amp;lt;br&gt;in an Odd shape] %% Comments after double percent signs e((Inner / circle&amp;lt;br&gt;and some odd &amp;lt;br&gt;special characters)) --&gt; f(,.?!+-*ز) cyr[Cyrillic]--&gt;cyr2((Circle shape Начало)); classDef green fill:#9f6,stroke:#333,stroke-width:2px; classDef orange fill:#f96,stroke:#333,stroke-width:4px; class sq,e green class di orange graph TB sq[Square shape] --&gt; ci((Circle shape)) subgraph A subgraph od&gt;Odd shape]-- Two line&amp;lt;br&gt;edge comment --&gt; ro di{Diamond with &amp;lt;br/&gt; line break} -.-&gt; ro(Rounded&amp;lt;br&gt;square&amp;lt;br&gt;shape) di==&gt;ro2(Rounded square shape) end %% Notice that no text in shape are added here instead that is appended further down e --&gt; od3&gt;Really long text with linebreak&lt;br&gt;in an Odd shape] %% Comments after double percent signs e((Inner / circle&lt;br&gt;and some odd &lt;br&gt;special characters)) --&gt; f(,.?!+-*ز) cyr[Cyrillic]--&gt;cyr2((Circle shape Начало)); classDef green fill:#9f6,stroke:#333,stroke-width:2px; classDef orange fill:#f96,stroke:#333,stroke-width:4px; class sq,e green class di orange Basic sequence diagram %% Sequence diagram code sequenceDiagram Alice -&gt;&gt; Bob: Hello Bob, how are you? Bob--&gt;&gt;John: How about you John? Bob--x Alice: I am good thanks! Bob-x John: I am good thanks! Note right of John: Bob thinks a long&amp;lt;br/&gt;long time, so long&amp;lt;br/&gt;that the text does&amp;lt;br/&gt;not fit on a row. Bob--&gt;Alice: Checking with John... Alice-&gt;John: Yes... John, how are you? sequenceDiagram Alice-&gt;&gt; Bob: Hello Bob, how are you? Bob--&gt;&gt; John: How about you John? Bob--x Alice: I am good thanks! Bob-x John: I am good thanks! Note right of John: Bob thinks a long&lt;br/&gt;long time, so long&lt;br/&gt;that the text does&lt;br/&gt;not fit on a row. Bob--&gt;Alice: Checking with John... Alice-&gt;John: Yes... John, how are you? Loops, alt and opt %% Sequence diagram code sequenceDiagram loop Daily query Alice-&amp;gt;&amp;gt;Bob: Hello Bob, how are you? alt is sick Bob-&amp;gt;&amp;gt;Alice: Not so good :( else is well Bob-&amp;gt;&amp;gt;Alice: Feeling fresh like a daisy end opt Extra response Bob-&amp;gt;&amp;gt;Alice: Thanks for asking end end sequenceDiagram loop Daily query Alice-&gt;&gt;Bob: Hello Bob, how are you? alt is sick Bob-&gt;&gt;Alice: Not so good :( else is well Bob-&gt;&gt;Alice: Feeling fresh like a daisy end opt Extra response Bob-&gt;&gt;Alice: Thanks for asking end end Message to self in loop %% Sequence diagram code sequenceDiagram participant Alice participant Bob Alice-&gt;&gt;John: Hello John, how are you? loop Healthcheck John-&gt;&gt;John: Fight against hypochondria end Note right of John: Rational thoughts&amp;lt;br/&gt;prevail... John--&gt;&gt;Alice: Great! John-&gt;&gt;Bob: How about you? Bob--&gt;&gt;John: Jolly good! sequenceDiagram participant Alice participant Bob Alice-&gt;&gt;John: Hello John, how are you? loop Healthcheck John-&gt;&gt;John: Fight against hypochondria end Note right of John: Rational thoughts&lt;br/&gt;prevail... John--&gt;&gt;Alice: Great! John-&gt;&gt;Bob: How about you? Bob--&gt;&gt;John: Jolly good!",
    "tags": "",
    "url": "/peripheral_brain/javascript/mermaid-7.0.0/docs/content/demos.html"
  },{
    "title": "",
    "text": "Development Updating the documentation Getting the development environment up Fork the gh-pages branch in the the mermaid repository Do npm install Working with the documentation The html files are generated from the source and the markdown files in the docs folder. The site generation is done using the docker.js framework with the command below. docker -i ../mermaid/ -x \"*git*|*travis*|*bin*|*dist*|*node_modules*|*gulp*|*lib*|*editor*|*conf*|*scripts*|*test*|*htmlDocs*\" --extras mermaid -w -o htmlDocs Thus … One important thing to remember. * Do not edit the html files directly! * Those changes will be overwritten when the site is re-generated. Committing the changes Do a pull request to merge the changes to the site. Things to be done in order to add a new diagram type Step 1: Grammar &amp; Parsing Grammar This would be to define a jison grammar for the new diagram type. That should start with a way to identify that the text in the mermaid tag is a diagram of that type. Create a new folder under diagrams for your new diagram type and a parser folder in it. This leads us to step 2. For instance: the flowchart starts with the keyword graph. the sequence diagram starts with the keyword sequenceDiagram Store data found during parsing There are some jison specific sub steps here where the parser stores the data encountered when parsing the diagram, this data is later used by the renderer. You can during the parsing call a object provided to the parser by the user of the parser. This object can be called during parsing for storing data. statement : 'participant' actor { $$='actor'; } | signal { $$='signal'; } | note_statement { $$='note'; } | 'title' message { yy.setTitle($2); } ; In the extract of the grammar above, it is defined that a call to the setTitle method in the data object will be done when parsing and the title keyword is encountered. Note: Make sure that the parseError function for the parser is defined and calling mermaidPAI.parseError this way a common way of detecting parse errors is provided for the end-user. For more info look in the example diagram type: The yy object has the following function: exports.parseError = function(err,hash){ mermaidAPI.parseError(err,hash); }; when parsing the yy object is initialized as per below: var parser; parser = exampleParser.parser; parser.yy = db; Step 2: Rendering Write a renderer that given the data found during parsing renders the diagram. To look at an example look at sequendeRenderer.js rather then the flowchart renderer as this is a more generic example. Place the renderer in the diagram folder. Step 3: Detection of the new diagram type The second thing to do is to add the capability to detect the new new diagram to type to the detectType in utils.js. The detection should return a key for the new diagram type. Step 4: The final piece - triggering the rendering At this point when mermaid is trying to render the diagram, it will detect it as being of the new type but there will be no match when trying to render the diagram. To fix this add a new case in the switch statement in main.js:init this should match the diagram type returned from step number 2. The code in this new case statement should call the renderer for the diagram type with the data found by the parser as an argument. Usage of the parser as a separate module Setup var graph = require('./graphDb'); var flow = require('./parser/flow'); flow.parser.yy = graph; Parsing flow.parser.parse(text); Data extraction // Javascript example graph.getDirection(); graph.getVertices(); graph.getEdges(); The parser is also exposed in the mermaid api by calling: var parser = mermaid.getParser(); Note that the parse needs a graph object to store the data as per: flow.parser.yy = graph; Look at graphDb.js for more details on that object.",
    "tags": "",
    "url": "/peripheral_brain/javascript/mermaid-7.0.0/docs/content/development.html"
  },{
    "title": "The 1st 5 Minutes",
    "text": "ACS MONA Morphine 2-4mg IV q5-30min in increments of 2-8mg PRN BP and RR after each bolus Can consider meperidine or other opiod D/C all NSAIDs and avoid all NSAIDs during admission O2 to sat of 95% if &lt; 90% on presentation SL NTG 0.4mg q5min x3, if non-responsive start IV NTG 5-10mcg/min to 75-100mcg/min (Max 200, consider 1-2min bolus of 400mcg/min to load) Verify NO PDEIs w/i 24-36hr IV Contraindicated w/ SBP &lt; 90; &gt; 30 mmHg change from baseline; Bradycardia or Tachycardia; Suspected RV Infarction Monitor BP and HR q2h while on IV ASA 325mg Chewed and Swallowed on presentation Consider anxiolytics to decrease HR and demand Consider PCI for STEMI Consult ACS for further management Stroke Labs Conduct NIHSS (National Institutes of Health Stroke Scale) Head CT to r/o hemorrhagic stroke Monitor BP / O2Sat BG BMP CBC INR / aPTT EKG Echo Pt is NPO until swallow study conducted Initial Therapies Manage BG if abnormal Hypoglycemia can result in stroke SSx Hyperglycemia above 180 mg/dL can result in higher morbidity / mortality Consider thrombolytics for ischemic strokes (must r/o hemorrhagic) Manage HTN to &lt; 220/120 for non-thrombolytic pts, &lt; 180/105 for thrombolysis IV antihypertensives warranted, do not lower BP excessively, as elevated BP may help perfuse partially occluded areas Agressive BP control can limit stroke recurrence, long-term neuro deficits, an decrease risk of cerebral edema; however concern from above usually wins, attempt to balance (i.e 150s instead of 170s or 110s) Thrombolysis Dosing Must satisfy inclusion / exclusion criteria below 0.9 mg/kg NTE 90mg Total dose 10% (0.09 mg/kg) IVPB over 1min 90% (0.81 mg/kg) IV over 60min Give w/i 60min of arrival Keep BP &lt; 180/105 Monitor q15min x2h then q30min x 6h then q1h x16hr Can begin to lower to outpt goal after 24h Avoid all antiplatelets and anticoagulants for 24hr post-admin SEs Bleeding Stroke Conversion Cerebral Edema Inclusion Criteria Ischemic stroke confirmed by imaging &lt; 3hrs from SSx onset Extended interval available, see below Some evidence for imaging-based determination of thrombolysis eligbility here, but not currently in guidelines ≥ 18yo Exclusion Criteria Evidence of active internal bleed Hx of intracranial hemorrhage Previous stroke or head trauma in less than 3mo GI or GU hemorrhage in ≤ 21d Major surgery in ≤ 14d MI in ≤ 3mo BP &gt; 185/110 at administration time BG &lt; 50 mg/dL Plt &lt; 100k Current anticoag w/ INR &gt; 1.7 or aPTT &gt; 45s NOACs CI tPA Reversible exclusion criteria Extended tPA Window &lt; 4.5hrs after SSx onset Add the following to the exclusion criteria Age ≥ 80 Hx of Stroke w/ DM Any recent anticoag use NIHSS &gt; 25 BP Control Use common IV antihypertensives discussed in HTN Crisis section Labetalol 10-20mg IVPB q10-20min NTE 300mg Nicardipine 5mg/hr IV titrated q5min NTE 15 mg/hr Nitroprusside 0.5-10 mcg/kg/min titrated (preferable if DBP &gt; 140) Transfusion for Severe Acute Anemia Criteria Acutely Symptomatic Hgb &lt; 8 (some argue 7) Admin PRBCs Type and cross before admin 1 U &amp;approx; 300 mL &amp;approx; Δ 1 g/dL Hgb Consider activation of massive transfusion protocol Hemorrhaging / trauma pts may require infusions of FFP and Plt as well to sustain coagulation, strongly consider before using large volumes of crystalloid Pts refusing transfusion can be given high dose iron, B12, and Epo, look up protocol Complications Iron Overload Infection (HIV etc, rare) Hyperviscosity syndrome Alloimmunization Volume overload Transfusion reactions",
    "tags": "",
    "url": "/peripheral_brain/firstFive"
  },{
    "title": "",
    "text": "Flowcharts - Basic Syntax Graph This statement declares a new graph and the direction of the graph layout. %% Example code graph TD This declares a graph oriented from top to bottom. graph TD Start --&gt; Stop %% Example code graph LR This declares a graph oriented from left to right. Possible directions are: TB - top bottom BT - bottom top RL - right left LR - left right TD - same as TB graph LR Start --&gt; Stop Nodes &amp; shapes A node (default) graph LR id1 graph LR id Note that the id is what is displayed in the box. A node with text It is also possible to set text in the box that differs from the id. If this is done several times, it is the last text found for the node that will be used. Also if you define edges for the node later on, you can omit text definitions. The one previously defined will be used when rendering the box. graph LR id1[This is the text in the box] graph LR id1[This is the text in the box] A node with round edges graph LR id1(This is the text in the box); graph LR id1(This is the text in the box) A node in the form of a circle graph LR id1((This is the text in the circle)); graph LR id1((This is the text in the circle)) A node in an asymetric shape graph LR id1&gt;This is the text in the box] graph LR id1&gt;This is the text in the box] Currently only the shape above is possible and not its mirror. This might change with future releases. A node (rhombus) graph LR id1{This is the text in the box} graph LR id1{This is the text in the box} Links between nodes Nodes can be connected with links/edges. It is possible to have different types of links or attach a text string to a link. A link with arrow head graph LR A--&gt;B graph LR; A--&gt;B An open link graph LR A --- B graph LR; A --- B Text on links A-- This is the text --- B or A---|This is the text|B; graph LR; A-- This is the text ---B A link with arrow head and text A--&gt;|text|B graph LR; A--&gt;|text|B or A-- text --&gt;B graph LR; A-- text --&gt;B Dotted link -.-&gt; graph LR; A-.-&gt;B; Dotted link with text -. text .-&gt; graph LR; A-. text .-&gt; B Thick link ==&gt; graph LR; A ==&gt; B Thick link with text == text ==&gt; graph LR; A == text ==&gt; B Special characters that break syntax It is possible to put text within quotes in order to render more troublesome characters. As in the example below: graph LR d1[\"This is the (text) in the box\"] graph LR id1[\"This is the (text) in the box\"] Entity codes to escape characters It is possible to escape characters using the syntax examplified here. The flowchart defined by the following code: graph LR A[\"A double quote:#quot;\"] --&gt;B[\"A dec char:#9829;\"] This would render to the diagram below: graph LR A[\"A double quote:#quot;\"] --&gt;B[\"A dec char:#9829;\"] Subgraphs subgraph title graph definition end An example below: %% Subgraph example graph TB subgraph one a1--&gt;a2 end subgraph two b1--&gt;b2 end subgraph three c1--&gt;c2 end c1--&gt;a2 graph TB c1--&gt;a2 subgraph one a1--&gt;a2 end subgraph two b1--&gt;b2 end subgraph three c1--&gt;c2 end Interaction It is possible to bind a click event to a node, the click can lead to either a javascript callback or to a link which will be opened in a new browser tab. click nodeId callback nodeId is the id of the node callback is the name of a javascript function defined on the page displaying the graph, the function will be called with the nodeId as parameter. Examples of tooltip usage below: &amp;lt;script&amp;gt; var callback = function(){ alert(&amp;#39;A callback was triggered&amp;#39;); } &amp;lt;script&amp;gt; graph LR; A--&gt;B; click A callback \"Tooltip for a callback\" click B \"http://www.github.com\" \"This is a tooltip for a link\" The tooltip text is surrounded in double quotes. The styles of the tooltip are set by the class .mermaidTooltip. graph LR; A--&gt;B; click A callback \"Tooltip\" click B \"http://www.github.com\" \"This is a link\" The tooltip functionality and the ability to link to urls are available from version 0.5.2. When integration mermaid using the mermaidAPI #mermaidapi the function that binds the events need to be run when the finished graph has been added to the page. This is described in the API usage section. Styling and classes Styling links It is possible to style links. For instance you might want to style a link that is going backwards in the flow. As links have no ids in the same way as nodes, some other way of deciding what style the links should be attached to is required. Instead of ids, the order number of when the link was defined in the graph is used. In the example below the style defined in the linkStyle statement will belong to the fourth link in the graph: linkStyle 3 stroke:#ff3,stroke-width:4px; Styling a node It is possible to apply specific styles such as a thicker border or a different background color to a node. %% Example code graph LR id1(Start)--&gt;id2(Stop) style id1 fill:#f9f,stroke:#333,stroke-width:4px; style id2 fill:#ccf,stroke:#f66,stroke-width:2px,stroke-dasharray: 5, 5; graph LR id1(Start)--&gt;id2(Stop) style id1 fill:#f9f,stroke:#333,stroke-width:4px style id2 fill:#ccf,stroke:#f66,stroke-width:2px,stroke-dasharray: 5, 5 Classes More convenient then defining the style every time is to define a class of styles and attach this class to the nodes that should have a different look. a class definition looks like the example below: classDef className fill:#f9f,stroke:#333,stroke-width:4px; Attachment of a class to a node is done as per below: class nodeId1 className; It is also possible to attach a class to a list of nodes in one statement: class nodeId1,nodeId2 className; Css classes It is also possible to pre dine classes in css styles that can be applied from the graph definition as in the example below: Example style &lt;style&gt; .cssClass &gt; rect{ fill:#FF0000; stroke:#FFFF00; stroke-width:4px; } &lt;/style&gt; Example definition graph LR; A--&gt;B[AAA&lt;span&gt;BBB&lt;/span&gt;]; B--&gt;D; class A cssClass; Class definitions in the graph defnition is broken in version 0.5.1 but has been fixed in the master branch of mermaid. This fix will be included in 0.5.2 Default class If a class is named default it will be assigned to all classes without specific class definitions. classDef default fill:#f9f,stroke:#333,stroke-width:4px; Basic support for fontawesome It is possible to add icons from fontawesome. In order to do so, you need to add the fontawesome as described in the instructions at the fontawesome web site. The icons are acessed via the syntax fa:#icon class name#. The example code below graph TD B[\"fa:fa-twitter for peace\"] B--&gt;C[fa:fa-ban forbidden] B--&gt;D(fa:fa-spinner); B--&gt;E(A fa:fa-camera-retro perhaps?); Would render the graph below: graph TD B[\"fa:fa-twitter for peace\"] B--&gt;C[fa:fa-ban forbidden] B--&gt;D(fa:fa-spinner); B--&gt;E(A fa:fa-camera-retro perhaps?); Support for fontawesome has been comitted to the master branch and will be included in 0.5.3 Graph declarations with spaces between vertices and link and without semicolon In graph declarations, the statements also can now end without a semicolon. After release 0.2.16, ending a graph statement with semicolon is just optional. So the below graph declaration is also valid along with the old declarations of the graph. A single space is allowed between vertices and the link. However there should not be any space between a vertex and its text and a link and its text. The old syntax of graph declaration will also work and hence this new feature is optional and is introduce to improve readability. Below is the new declaration of the graph edges which is also valid along with the old declaration of the graph edges. A[Hard edge] --&gt;|Link text| B(Round edge) B --&gt; C{Decision} C --&gt;|One| D[Result one] C --&gt;|Two| E[Result two] graph LR A[Hard edge] --&gt;|Link text| B(Round edge) B --&gt; C{Decision} C --&gt;|One| D[Result one] C --&gt;|Two| E[Result two]",
    "tags": "",
    "url": "/peripheral_brain/javascript/mermaid-7.0.0/docs/content/flowchart.html"
  },{
    "title": "Formulas",
    "text": "Dosing and Body Weights Acid-Base Nitrogen Balance Fluids and Electrolytes Anticoagulation EKG Interpretation Pharmacokinetics General PK 1-Compartment Model",
    "tags": "",
    "url": "/peripheral_brain/formulas"
  },{
    "title": "",
    "text": "Gant diagrams A Gantt chart is a type of bar chart, first developed by Karol Adamiecki in 1896, and independently by Henry Gantt in the 1910s, that illustrates a project schedule. Gantt charts illustrate the start and finish dates of the terminal elements and summary elements of a project. Mermaid can render Gantt diagrams. The code snippet below: %% Example of sequence diagram gantt title A Gantt Diagram section Section A task :a1, 2014-01-01, 30d Another task :after a1 , 20d section Another Task in sec :2014-01-12 , 12d anther task : 24d Renders the following diagram: gantt title A Gantt Diagram dateFormat YYYY-MM-DD section Section A task :a1, 2014-01-01, 30d Another task :after a1 , 20d section Another Task in sec :2014-01-12 , 12d anther task : 24d Syntax %% Example with slection of syntaxes gantt dateFormat YYYY-MM-DD title Adding GANTT diagram functionality to mermaid section A section Completed task :done, des1, 2014-01-06,2014-01-08 Active task :active, des2, 2014-01-09, 3d Future task : des3, after des2, 5d Future task2 : des4, after des3, 5d section Critical tasks Completed task in the critical line :crit, done, 2014-01-06,24h Implement parser and jison :crit, done, after des1, 2d Create tests for parser :crit, active, 3d Future task in critical line :crit, 5d Create tests for renderer :2d Add to mermaid :1d section Documentation Describe gantt syntax :active, a1, after des1, 3d Add gantt diagram to demo page :after a1 , 20h Add another diagram to demo page :doc1, after a1 , 48h section Last section Describe gantt syntax :after doc1, 3d Add gantt diagram to demo page : 20h Add another diagram to demo page : 48h Renders like below: gantt dateFormat YYYY-MM-DD title Adding GANTT diagram functionality to mermaid section A section Completed task :done, des1, 2014-01-06,2014-01-08 Active task :active, des2, 2014-01-09, 3d Future task : des3, after des2, 5d Future task2 : des4, after des3, 5d section Critical tasks Completed task in the critical line :crit, done, 2014-01-06,24h Implement parser and jison :crit, done, after des1, 2d Create tests for parser :crit, active, 3d Future task in critical line :crit, 5d Create tests for renderer :2d Add to mermaid :1d section Documentation Describe gantt syntax :active, a1, after des1, 3d Add gantt diagram to demo page :after a1 , 20h Add another diagram to demo page :doc1, after a1 , 48h section Last section Describe gantt syntax :after doc1, 3d Add gantt diagram to demo page : 20h Add another diagram to demo page : 48h title Tbd Sections statements Tbd Setting dates Tbd Date format Tbd Diagram definition Input Example Description: YYYY 2014 4 digit year YY 14 2 digit year Q 1..4 Quarter of year. Sets month to first month in quarter. M MM 1..12 Month number MMM MMMM January..Dec Month name in locale set by moment.locale() D DD 1..31 Day of month Do 1st..31st Day of month with ordinal DDD DDDD 1..365 Day of year X 1410715640.579 Unix timestamp x 1410715640579 Unix ms timestamp Input Example Description H HH 0..23 24 hour time h hh 1..12 12 hour time used with a A. a A am pm Post or ante meridiem m mm 0..59 Minutes s ss 0..59 Seconds S 0..9 Tenths of a second SS 0..99 Hundreds of a second SSS 0..999 Thousandths of a second Z ZZ +12:00 Offset from UTC as +-HH:mm, +-HHmm, or Z More info in: http://momentjs.com/docs/#/parsing/string-format/ Scale %a - abbreviated weekday name. %A - full weekday name. %b - abbreviated month name. %B - full month name. %c - date and time, as \"%a %b %e %H:%M:%S %Y\". %d - zero-padded day of the month as a decimal number [01,31]. %e - space-padded day of the month as a decimal number [ 1,31]; equivalent to %_d. %H - hour (24-hour clock) as a decimal number [00,23]. %I - hour (12-hour clock) as a decimal number [01,12]. %j - day of the year as a decimal number [001,366]. %m - month as a decimal number [01,12]. %M - minute as a decimal number [00,59]. %L - milliseconds as a decimal number [000, 999]. %p - either AM or PM. %S - second as a decimal number [00,61]. %U - week number of the year (Sunday as the first day of the week) as a decimal number [00,53]. %w - weekday as a decimal number [0(Sunday),6]. %W - week number of the year (Monday as the first day of the week) as a decimal number [00,53]. %x - date, as \"%m/%d/%Y\". %X - time, as \"%H:%M:%S\". %y - year without century as a decimal number [00,99]. %Y - year with century as a decimal number. %Z - time zone offset, such as \"-0700\". %% - a literal \"%\" character. More info in: https://github.com/mbostock/d3/wiki/Time-Formatting Styling Styling of the a sequence diagram is done by defining a number of css classes. During rendering these classes are extracted from the Classes used Class Description actor Style for the actor box at the top of the diagram. text.actor Styles for text in the actor box at the top of the diagram. actor-line The vertical line for an actor. messageLine0 Styles for the solid message line. messageLine1 Styles for the dotted message line. messageText Defines styles for the text on the message arrows. labelBox Defines styles label to left in a loop. labelText Styles for the text in label for loops. loopText Styles for the text in the loop box. loopLine Defines styles for the lines in the loop box. note Styles for the note box. noteText Styles for the text on in the note boxes. Sample stylesheet .grid .tick { stroke: lightgrey; opacity: 0.3; shape-rendering: crispEdges; } .grid path { stroke-width: 0; } #tag { color: white; background: #FA283D; width: 150px; position: absolute; display: none; padding:3px 6px; margin-left: -80px; font-size: 11px; } #tag:before { border: solid transparent; content: ' '; height: 0; left: 50%; margin-left: -5px; position: absolute; width: 0; border-width: 10px; border-bottom-color: #FA283D; top: -20px; } .taskText { fill:white; text-anchor:middle; } .taskTextOutsideRight { fill:black; text-anchor:start; } .taskTextOutsideLeft { fill:black; text-anchor:end; } Configuration Is it possible to adjust the margins for rendering the sequence diagram. This is done by defining the sequenceConfig part of the configuration object. Read more about it here. How to use the CLI is described in the [mermaidCLI]((http://knsv.github.io/mermaid/index.html#mermaidCLI) page.",
    "tags": "",
    "url": "/peripheral_brain/javascript/mermaid-7.0.0/docs/content/gantt.html"
  },{
    "title": "",
    "text": "mermaid Generation of diagrams and flowcharts from text in a similar manner as markdown. Ever wanted to simplify documentation and avoid heavy tools like Visio when explaining your code? This is why mermaid was born, a simple markdown-like script language for generating charts from text via javascript. Try it using our editor. Code examples below: An example of a flowchart graph TD; A--&gt;B; A--&gt;C; B--&gt;D; C--&gt;D; An example of a sequence diagram sequenceDiagram participant Alice participant Bob Alice-&gt;John: Hello John, how are you? loop Healthcheck John-&gt;John: Fight against hypochondria end Note right of John: Rational thoughts &amp;lt;br/&gt;prevail... John--&gt;Alice: Great! John-&gt;Bob: How about you? Bob--&gt;John: Jolly good! Example code for a gantt diagram gantt dateFormat YYYY-MM-DD title Adding GANTT diagram functionality to mermaid section A section Completed task :done, des1, 2014-01-06,2014-01-08 Active task :active, des2, 2014-01-09, 3d Future task : des3, after des2, 5d Future task2 : des4, after des3, 5d section Critical tasks Completed task in the critical line :crit, done, 2014-01-06,24h Implement parser and jison :crit, done, after des1, 2d Create tests for parser :crit, active, 3d Future task in critical line :crit, 5d Create tests for renderer :2d Add to mermaid :1d Play with mermaid using this editor or this live editor. Credits Many thanks to the d3 and dagre-d3 projects for providing the graphical layout and drawing libraries! Thanks also to the js-sequence-diagram project for usage of the grammar for the sequence diagrams. Mermaid was created by Knut Sveidqvist for easier documentation. Knut has not done all work by himself, here is the full list of the projects contributors. Downstream projects Mermaid is supported in a number of publishing systems and editors. Please report if a plugin/editor is missing from the list below: Support in LightPaper 1.2+. Howto. Discout with code MERMAID_25 gitbook-plugin light table Confluence plugin Using mermaid via docpad Using mermaid in Jekyll Using mermaid via Octopress Mardown editor Haroopad Plugin for atom Markdown Plus Vim Plugin Sphinx extension Pandoc filter hads Online live editor An editor is available for creating diagrams. With it you can quickly start writing mermaid diagrams. It is possible to: save the result as a svg get a link to a viewer of the diagram get a link to edit of the diagram to share a diagram so that someone else can tweak it and send a new link back Editor",
    "tags": "",
    "url": "/peripheral_brain/javascript/mermaid-7.0.0/docs/content/"
  },{
    "title": "Lab Values",
    "text": "ABG pH / paCO2 / paO2 / [HCO3]- / O2 Sat Lab Low High Units pH 7.35 7.45 n/a paCO2 35 45 mmHg paO2 80 100 mmHg HCO3- 22 26 mEq/L O2 Sat 95% 100% % Saturation Electrolytes Lab Low High Units pH 7.35 7.45 n/a Na+ 135 145 mEq/L Cl- 95 105 mEq/L K+ 3.5 5 mEq/L Ca2+ 8.5 10.5 mg/dL Ionized Ca2+ 4.6 5.1 mg/dL HCO3- 22 26 mEq/L Mg2+ 1.5 2.5 mg/dL PO43- 2.5 4.5 mg/dL Osm 275 290 mOsm/L Anion Gap 3 11 mEq/L Chem7 Na K Cl Bicarb BUN SCr Gluc Hematology WBC Plt Hgb Hct Lab Low High Unit Hgb (M) 13.5 17.5 g/dL Hgb (F) 12 16 g/dL Hct (M) 41 53 % Hct (F) 36 46 % RBC (M) 4.5 5.9 M/mcL RBC (F) 4.1 5.1 M/mcL MCV 80 100 fL RDW 11 15 % Folate 1.8 16 ng/mL B12 100 900 pg/mL Cells Low % High % Segmented 45 75 Bands 3 5 Lymphocytes 20 40 Monocytes 2 8 Eosinophils 0 4 Basophils 2 2 Lab Low High Unit Ferritin 10 20 mcg/L Serum Iron 60 150 mcg/dL Transferrin 20 50 % TIBC 250 400 mcg/dL Anticoagulation Monitoring Test Evaluating Low High Units Platelet Count Bone Marrow 150 450 k/mm3 PT Extrinsic Pathway 12 14 sec INR Extrinsic Pathway - 1.1 n/a aPTT Intrinsic Pathway 26 33 sec EKG Normal Values Measure Interval (ms) PR Interval 120-200 QRS 80-120 QT* 380-460 QTc (Male)* 360-470 QTc (Female)* 360-480 *High risk of Torsades w/ QTc ≥500ms",
    "tags": "",
    "url": "/peripheral_brain/lab_values"
  },{
    "title": "",
    "text": "mermaid CLI Installing mermaid globally (npm install -g mermaid) will expose the mermaid command to your environment, allowing you to generate PNGs from any file containing mermaid markup via the command line. Note: The mermaid command requires PhantomJS (version ^1.9.0) to be installed and available in your $PATH, or you can specify it’s location with the -e option. For most environments, npm install -g phantomjs will satisfy this requirement. Usage $ mermaid --help Usage: mermaid [options] &lt;file&gt;... file The mermaid description file to be rendered Options: -s --svg Output SVG instead of PNG (experimental) -p --png If SVG was selected, and you also want PNG, set this flag -o --outputDir Directory to save files, will be created automatically, defaults to `cwd` -e --phantomPath Specify the path to the phantomjs executable -c --sequenceConfig Specify the path to the file with the configuration to be applied in the sequence diagram -h --help Show this message -v --verbose Show logging -w --width width of the generated png (number) --version Print version and quit mermaid testGraph.mmd mermaid testGraph.mmd -w 980 Sequence diagram configuration The –sequenceConfig option allows overriding the sequence diagram configuration. It could be useful to increase the width between actors, the notes width or the margin to fit some large texts that are not well rendered with the default configuration, for example. The content of the file must be a JSON like this: { \"diagramMarginX\": 100, \"diagramMarginY\": 10, \"actorMargin\": 150, \"width\": 150, \"height\": 65, \"boxMargin\": 10, \"boxTextMargin\": 5, \"noteMargin\": 10, \"messageMargin\": 35 } These properties will override the default values and if a property is not set in this object, it will left it empty and could raise an error. The current properties (measured in px) are: diagramMarginX: Size of the empty space to add at the left-right of the diagram. diagramMarginY: Size of the empty space to add at the top-bottom of the diagram. actorMargin: Horizontal space between each participant. The arrows between them would have this size too. width: Width of the participant box. height: Height of the participant box. boxMargin: Blank area around loop boxes. boxTextMargin: Blank area between the text and the border in a loop box. noteMargin: Size of the empty space around a note. messageMargin: Space between messages CLI Known Issues SVG output currently does some replacement on text, as mermaid’s SVG output is only appropriate for browsers. Text color and background color is not yet replicated; please use PNGs for most purposes until this is resolved. SVG output is decidedly non-standard. It works, but may cause issues in some viewers.",
    "tags": "",
    "url": "/peripheral_brain/javascript/mermaid-7.0.0/docs/content/mermaidCLI.html"
  },{
    "title": "Sequence Diagram",
    "text": "Sequence diagrams A Sequence diagram is an interaction diagram that shows how processes operate with one another and in what order. Mermaid can render sequence diagrams. The code snippet below: %% Example of sequence diagram sequenceDiagram Alice-&gt;&gt;John: Hello John, how are you? John--&gt;&gt;Alice: Great! Renders the following diagram: sequenceDiagram Alice-&gt;&gt;John: Hello John, how are you? John--&gt;&gt;Alice: Great! Syntax Participants The participants can be defined implicitly as in the first example on this page. The participants or actors are rendered in order of appearance in the diagram source text. Sometimes you might want to show the participants in a different order than how they appear in the first message. It is possible to specify the actor’s order of appearance by doing the following: %% Example of sequence diagram sequenceDiagram participant John participant Alice Alice-&gt;&gt;John: Hello John, how are you? John--&gt;&gt;Alice: Great! Renders to the diagram below: sequenceDiagram participant John participant Alice Alice-&gt;&gt;John: Hello John, how are you? John--&gt;&gt;Alice: Great! Messages Messages can be of two displayed either solid or with a dotted line. [Actor][Arrow][Actor]:Message text There are six types of arrows currently supported: -&gt; which will render a solid line without arrow –&gt; which will render a dotted line without arrow -» which will render a solid line with arrowhead –» which will render a dotted line with arrowhead -x which will render a solid line with a cross at the end (async) –x which will render a dotted line with a cross at the end (async) Activations It is possible to activate and deactivate an actor. (de)activation can be dedicated declarations: sequenceDiagram Alice-&gt;&gt;John: Hello John, how are you? activate John John--&gt;&gt;Alice: Great! deactivate John Renders to the diagram below: sequenceDiagram Alice-&gt;&gt;John: Hello John, how are you? activate John John--&gt;&gt;Alice: Great! deactivate John There is also a shortcut notation by appending +/- suffix to the message arrow: sequenceDiagram Alice-&gt;&gt;+John: Hello John, how are you? John--&gt;&gt;-Alice: Great! Activations can be stacked for same actor: sequenceDiagram Alice-&gt;&gt;+John: Hello John, how are you? Alice-&gt;&gt;+John: John, can yoy hear me? John--&gt;&gt;-Alice: Hi Alice, I can hear you! John--&gt;&gt;-Alice: I feel great! Stacked activations look like this: sequenceDiagram Alice-&gt;&gt;+John: Hello John, how are you? Alice-&gt;&gt;+John: John, can yoy hear me? John--&gt;&gt;-Alice: Hi Alice, I can hear you! John--&gt;&gt;-Alice: I feel great! Notes It is possible to add notes to a sequence diagram. This is done by the notation Note [ right of | left of | over ] [Actor]: Text in note content See the example below: %% Example of sequence diagram sequenceDiagram participant John Note right of John: Text in note Renders to the diagram below: sequenceDiagram participant John Note right of John: Text in note It is also possible to create notes spanning two participants: sequenceDiagram Alice-&gt;John: Hello John, how are you? Note over Alice,John: A typical interaction sequenceDiagram Alice-&gt;John: Hello John, how are you? Note over Alice,John: A typical interaction Loops It is possible to express loops in a sequence diagram. This is done by the notation loop Loop text ... statements ... end See the example below %% Example of sequence diagram sequenceDiagram Alice-&gt;John: Hello John, how are you? loop Reply every minute John--&gt;Alice: Great! end sequenceDiagram Alice-&gt;John: Hello John, how are you? loop Every minute John--&gt;Alice: Great! end Alt It is possible to express alternative paths in a sequence diagram. This is done by the notation alt Describing text ... statements ... else ... statements ... end or if there is sequence that is optional (if without else). opt Describing text ... statements ... end See the example below %% Example of sequence diagram sequenceDiagram Alice-&gt;&gt;Bob: Hello Bob, how are you? alt is sick Bob-&gt;&gt;Alice: Not so good :( else is well Bob-&gt;&gt;Alice: Feeling fresh like a daisy end opt Extra response Bob-&gt;&gt;Alice: Thanks for asking end sequenceDiagram Alice-&gt;&gt;Bob: Hello Bob, how are you? alt is sick Bob-&gt;&gt;Alice: Not so good :( else is well Bob-&gt;&gt;Alice: Feeling fresh like a daisy end opt Extra response Bob-&gt;&gt;Alice: Thanks for asking end Styling Styling of the a sequence diagram is done by defining a number of css classes. During rendering these classes are extracted from the Classes used Class Description actor Style for the actor box at the top of the diagram. text.actor Styles for text in the actor box at the top of the diagram. actor-line The vertical line for an actor. messageLine0 Styles for the solid message line. messageLine1 Styles for the dotted message line. messageText Defines styles for the text on the message arrows. labelBox Defines styles label to left in a loop. labelText Styles for the text in label for loops. loopText Styles for the text in the loop box. loopLine Defines styles for the lines in the loop box. note Styles for the note box. noteText Styles for the text on in the note boxes. Sample stylesheet body { background: white; } .actor { stroke: #CCCCFF; fill: #ECECFF; } text.actor { fill:black; stroke:none; font-family: Helvetica; } .actor-line { stroke:grey; } .messageLine0 { stroke-width:1.5; stroke-dasharray: \"2 2\"; marker-end:\"url(#arrowhead)\"; stroke:black; } .messageLine1 { stroke-width:1.5; stroke-dasharray: \"2 2\"; stroke:black; } #arrowhead { fill:black; } .messageText { fill:black; stroke:none; font-family: 'trebuchet ms', verdana, arial; font-size:14px; } .labelBox { stroke: #CCCCFF; fill: #ECECFF; } .labelText { fill:black; stroke:none; font-family: 'trebuchet ms', verdana, arial; } .loopText { fill:black; stroke:none; font-family: 'trebuchet ms', verdana, arial; } .loopLine { stroke-width:2; stroke-dasharray: \"2 2\"; marker-end:\"url(#arrowhead)\"; stroke: #CCCCFF; } .note { stroke: #decc93; stroke: #CCCCFF; fill: #fff5ad; } .noteText { fill:black; stroke:none; font-family: 'trebuchet ms', verdana, arial; font-size:14px; } Configuration Is it possible to adjust the margins for rendering the sequence diagram. This is done by defining mermaid.sequenceConfig or by the CLI to use a json file with the configuration. How to use the CLI is described in the mermaidCLI page. mermaid.sequenceConfig can be set to a JSON string with config parameters or the corresponding object. mermaid.sequenceConfig = { diagramMarginX:50, diagramMarginY:10, boxTextMargin:5, noteMargin:10, messageMargin:35, mirrorActors:true }; Possible configration params: Param Descriotion Default value mirrorActor Turns on/off the rendering of actors below the diagram as well as above it false bottomMarginAdj Adjusts how far down the graph ended. Wide borders styles with css could generate unwantewd clipping which is why this config param exists. 1",
    "tags": "",
    "url": "/peripheral_brain/javascript/mermaid-7.0.0/docs/content/sequenceDiagram.html"
  },{
    "title": "Sources",
    "text": "Cardiology ACS AHA NSTE-ACS Guidelines 2014 [^amsterdam2014]: Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes. Journal of the American College of Cardiology. 2014;64(24):e139-e228. doi:10.1016/j.jacc.2014.09.017 AHA STEMI Guidelines [^ogara2013]: O’Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction. *Journal of the American College of Cardiology*. 2013;61(4):e78-e140. doi:[10.1016/j.jacc.2012.11.019](https://doi.org/10.1016/j.jacc.2012.11.019) Benign Early Repol vs Subtle LAD STEMI (4-variable) [^driver2017]: Driver BE, Khalil A, Henry T, Kazmi F, Adil A, Smith SW. A new 4-variable formula to differentiate normal variant ST segment elevation in V2-V4 (early repolarization) from subtle left anterior descending coronary occlusion - Adding QRS amplitude of V2 improves the model. *Journal of Electrocardiology*. 2017;50(5):561-569. doi:[10.1016/j.jelectrocard.2017.04.005](https://doi.org/10.1016/j.jelectrocard.2017.04.005) DAPT Duration in CAD [^levine2016]: Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease. *Journal of the American College of Cardiology*. 2016;68(10):1082-1115. doi:[10.1016/j.jacc.2016.03.513](https://doi.org/10.1016/j.jacc.2016.03.513) LBBB vs STEMI [^smith2012]: Smith SW, Dodd KW, Henry TD, Dvorak DM, Pearce LA. Diagnosis of ST-Elevation Myocardial Infarction in the Presence of Left Bundle Branch Block With the ST-Elevation to S-Wave Ratio in a Modified Sgarbossa Rule. *Annals of Emergency Medicine*. 2012;60(6):766-776. doi:[10.1016/j.annemergmed.2012.07.119](https://doi.org/10.1016/j.annemergmed.2012.07.119) Third Universal MI Definition [^thygesen]: Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD. Third Universal Definition of Myocardial Infarction. :16. STEMI PCI Update [^levine2015]: Levine GN, Bates ER, Blankenship JC, et al. 2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction. *Journal of the American College of Cardiology*. 2016;67(10):1235-1250. doi:[10.1016/j.jacc.2015.10.005](https://doi.org/10.1016/j.jacc.2015.10.005) HTN AHA HTN Guidelines [^whelton2018]: Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. *Journal of the American College of Cardiology*. 2018;71(19):e127-e248. doi:[10.1016/j.jacc.2017.11.006](https://doi.org/10.1016/j.jacc.2017.11.006) ACCP HTN Emergency [^benken2018]: Benken ST. ACCP Hypertensive Emergencies. 2018. Available at: https://www.accp.com/docs/bookstore/ccsap/ccsap2018b1_sample.pdf VTE VTE Treatment Guidelines [^kearon2016]: Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease. Chest. 2016;149(2):315-352. doi:[10.1016/j.chest.2015.11.026](https://doi.org/10.1016/j.chest.2015.11.026) VTE Prophylaxis [^gould2012]: Gould MK, Garcia DA, Wren SM, et al. Prevention of VTE in Nonorthopedic Surgical Patients. Chest. 2012;141(2):e227S-e277S. doi:[10.1378/chest.11-2297](https://doi.org/10.1378/chest.11-2297) CHF [^yancy2013]: Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2013;128(16). doi:[10.1161/CIR.0b013e31829e8776](https://doi.org/10.1161/CIR.0b013e31829e8776) [^yancy2017]: Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure. *Journal of the American College of Cardiology*. 2017;70(6):776-803. doi:[10.1016/j.jacc.2017.04.025 HLD [^grundy2018]: Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. *Journal of the American College of Cardiology*. November 2018. doi:[10.1016/j.jacc.2018.11.003](https://doi.org/10.1016/j.jacc.2018.11.003) [^jacobson2015]: Jacobson TA, Ito MK, Maki KC, et al. National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1—Full Report. *Journal of Clinical Lipidology*. 2015;9(2):129-169. doi:[10.1016/j.jacl.2015.02.003](https://doi.org/10.1016/j.jacl.2015.02.003) [^jentzer2015]: Jentzer JC, Coons JC, Link CB, Schmidhofer M. Pharmacotherapy Update on the Use of Vasopressors and Inotropes in the Intensive Care Unit. *Journal of Cardiovascular Pharmacology and Therapeutics*. 2015;20(3):249-260. doi:[10.1177/1074248414559838](https://doi.org/10.1177/1074248414559838) Critical Care Hypotension Management Push-Dose Pressors [^weingart2015]: Weingart S. Push-dose pressors for immediate blood pressure control. *Clinical and Experimental Emergency Medicine*. 2015;2(2):131-132. doi:[10.15441/ceem.15.010](https://doi.org/10.15441/ceem.15.010) [^hollenberg2011]: Hollenberg SM. Vasoactive Drugs in Circulatory Shock. American Journal of Respiratory and Critical Care Medicine. 2011;183(7):847-855. doi:[10.1164/rccm.201006-0972CI](https://doi.org/10.1164/rccm.201006-0972CI) [^jentzer2015]: Jentzer JC, Coons JC, Link CB, Schmidhofer M. Pharmacotherapy Update on the Use of Vasopressors and Inotropes in the Intensive Care Unit. Journal of Cardiovascular Pharmacology and Therapeutics. 2015;20(3):249-260. doi:[10.1177/1074248414559838](https://doi.org/10.1177/1074248414559838) [^overgaard2008]: Overgaard CB, Džavík V. Inotropes and Vasopressors: Review of Physiology and Clinical Use in Cardiovascular Disease. Circulation. 2008;118(10):1047-1056. doi:[10.1161/CIRCULATIONAHA.107.728840](https://doi.org/10.1161/CIRCULATIONAHA.107.728840) Stress Ulcer Prophylaxis [^barletta2016]: Barletta JF, Bruno JJ, Buckley MS, Cook DJ. Stress Ulcer Prophylaxis: *Critical Care Medicine*. 2016;44(7):1395-1405. doi:[10.1097/CCM.0000000000001872](https://doi.org/10.1097/CCM.0000000000001872) [^erstad1999]: Erstad BL, et al. ASHP Therapeutic Guidelines on Stress Ulcer Prophylaxis. 1999. ID Vancomycin Dosing Optimizing Vancomycin Dosing [^deryke2009]: Deryke CA, Alexander DP. Optimizing Vancomycin Dosing through Pharmacodynamic Assessment Targeting Area under the Concentration-Time Curve/Minimum Inhibitory Concentration. *Hospital Pharmacy*. 2009;44(9):751-765. doi:[10.1310/hpj4409-751](https://doi.org/10.1310/hpj4409-751) Vancomycin PK in Renal Dysfunction [^matzkel1984]: Matzke GR, McGory RW, Halstenson CE, Keane WF. Pharmacokinetics of vancomycin in patients with various degrees of renal function. *Antimicrobial Agents and Chemotherapy*. 1984;25(4):433-437. doi:[10.1128/AAC.25.4.433](https://doi.org/10.1128/AAC.25.4.433) ASHP Vancomycin Monitoring Recommendations [^rybak2009]: Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. *American Journal of Health-System Pharmacy*. 2009;66(1):82-98. doi:[10.2146/ajhp080434](https://doi.org/10.2146/ajhp080434) Aminoglycoside Dosing Stanford Health System Aminoglycoside Dosing Recommendations [^mui2017]: Mui, E. Stanford Health Care Aminoglycoside Dosing Guideline. 2017. [Link](http://med.stanford.edu/bugsanddrugs/dosing-protocols/_jcr_content/main/panel_builder/panel_0/download_2/file.res/Aminoglycoside%20Dosing%20Guide%202017-08-23.pdf) Extended Interval Aminoglycosides [^nicolau1995]: Nicolau DP, Freeman CD, Belliveau PP, Nightingale CH, Ross JW, Quintiliani R. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. *Antimicrobial Agents and Chemotherapy*. 1995;39(3):650-655. doi:[10.1128/AAC.39.3.650](https://doi.org/10.1128/AAC.39.3.650) Pulmononolgy GOLD COPD Guidelines 2018 [^goldCOPD]: Vogelmeier C, Agusti A, *et al*. Global Initiative for Chronic Obstructive Lung Disease. [Available Here](https://goldcopd.org/wp-content/uploads/2018/02/WMS-GOLD-2018-Feb-Final-to-print-v2.pdf) Textbooks Pharmacology DiPiro Pharmacotherapy [^dipiro]: DiPiro JT, ed. *Pharmacotherapy: A Pathophysiologic Approach*. Tenth edition. New York: McGraw-Hill Education; 2017. Emergency Medicine Tintinalli’s [^tintinalli]: Tintinalli JE, Stapczynski JS, Ma OJ, Cline D, Meckler GD, Yealy DM, eds. *Tintinalli’s Emergency Medicine: A Comprehensive Study Guide*. Eight edition. New York: McGraw-Hill Education; 2016. Websites Drug Resources Lexicomp [^lexi]: Lexi-Drugs. Lexicomp. Wolters Kluwer Health, Inc. Riverwoods, IL. Available at: [http://online.lexi.com](http://online.lexi.com).",
    "tags": "",
    "url": "/peripheral_brain/sources"
  },{
    "title": "Test",
    "text": "Option 1 Option 2",
    "tags": "",
    "url": "/peripheral_brain/test.html"
  },{
    "title": "",
    "text": "# Upgrading to from version -0.4.0 Some of the interfaces has been upgraded. ## Initialization mermaid_config is no longer used. Instead a call to mermaid initialize is done as in the example below: ### version 0.4.0 ``` mermaid_config = { startOnLoad:true }; ``` ### will look like below in version 0.5.0 ``` mermaid.initialize({ startOnLoad:true }); ```",
    "tags": "",
    "url": "/peripheral_brain/javascript/mermaid-7.0.0/docs/content/upgrading.html"
  },{
    "title": "Usage",
    "text": "# Usage ## Installation Either use the npm or bower package managers as per below: ``` bower install mermaid --save-dev ``` ``` npm install mermaid --save-dev ``` Or download a javascript bundle and a stylesheet, e.g. the urls below are for the default style and the all-in-one javascript - note that #version# should be replaced with version of choice: ``` https://cdn.rawgit.com/knsv/mermaid/#version#/dist/mermaid.css https://cdn.rawgit.com/knsv/mermaid/#version#/dist/mermaid.min.js ``` Ex: * [js version 6.0.0](https://cdn.rawgit.com/knsv/mermaid/6.0.0/dist/mermaid.min.js) Checkout the [latest version](https://github.com/knsv/mermaid/releases) and [other styles](https://github.com/knsv/mermaid/tree/master/dist) such as `forest` and `dark`. There are some bundles to choose from: * mermaid.js, mermaid.min.js This bundle contains all the javascript libraries you need to run mermaid * mermaid.slim.js, mermaid.slim.min.js This bundle does not contain d3 which is useful for sites that already have d3 in place * mermaidAPI.js, mermaidAPI.min.js, This bundle does not contain the web integration provided in the other packages but has a render function instead returns svg code. ** Important: ** > It's best to use a specific tag or commit hash in the URL (not a branch). Files are cached permanently after the first request. Read more about that at [https://rawgit.com/](https://rawgit.com/) ## Simple usage on a web page The easiest way to integrate mermaid on a web page requires two elements: 1. Inclusion of the mermaid framework in the html page using a script tag 2. A graph definition on the web page If these things are in place mermaid listens to the page load event and when fires, when the page has loaded, it will locate the graphs n the page and transform them to svg files. ### Include mermaid on your web page: ```html &lt;script src=&quot;mermaid.min.js&quot;&gt;&lt;/script&gt; &lt;script&gt;mermaid.initialize({startOnLoad:true});&lt;/script&gt; ``` Further down on your page mermaid will look for tags with ```class=\"mermaid\"```. From these tags mermaid will try to read the chart definiton which will be replaced with the svg chart. ### Define a chart like this: ``` &lt;div class=&quot;mermaid&quot;&gt; CHART DEFINITION GOES HERE &lt;/div&gt; ``` Would end up like this: ``` &lt;div class=&quot;mermaid&quot; id=&quot;mermaidChart0&quot;&gt; &lt;svg&gt; Chart ends up here &lt;/svg&gt; &lt;/div&gt; ``` An id is also added to mermaid tags without id. ### Simple full example: ```html graph LR A --- B B-->C[fa:fa-ban forbidden] B-->D(fa:fa-spinner); ``` ### Labels out of bounds If you use dynamically loaded fonts that are loaded through CSS, such as Google fonts, mermaid should wait for the whole page to have been loaded (dom + assets, particularly the fonts file). $(document).load(function() { mermaid.initialize(); }); over $(document).ready(function() { mermaid.initialize(); }); Not doing so will most likely result in mermaid rendering graphs that have labels out of bounds. The default integration in mermaid uses the window.load event to start rendering. ### Calling **mermaid.init** By default, **mermaid.init** will be called when the document is ready, finding all elements with ``class=\"mermaid\"``. If you are adding content after mermaid is loaded, or otherwise need finer-grained control of this behavior, you can call `init` yourself with: - a configuration object - some nodes, as - a node - an a array-like of nodes - or W3C selector that will find your nodes Example: ``` mermaid.init({noteMargin: 10}, \".someOtherClass\"); ``` Or with no config object, and a jQuery selection: ``` mermaid.init(undefined, $(\"#someId .yetAnotherClass\")); ``` This type of integration is deprecated instead the preferred way of handling more complex integration is to us the mermaidAPI instead. ## Usage with browserify The reader is assumed to know about CommonJS style of module handling and how to use browserify. If not a good place to start would be http://browserify.org/ website. Minimalistic javascript: ``` mermaid = require('mermaid'); console.log('Test page! mermaid version'+mermaid.version()); ``` Bundle the javascript with browserify. Us the created bundle on a web page as per example below: ```html &lt;!DOCTYPE html&gt; &lt;html&gt; &lt;head&gt; &lt;meta charset=&quot;UTF-8&quot;&gt; &lt;link rel=&quot;stylesheet&quot; href=&quot;mermaid.css&quot; /&gt; &lt;script src=&quot;bundle.js&quot;&gt;&lt;/script&gt; &lt;/head&gt; &lt;body&gt; &lt;div class=&quot;mermaid&quot;&gt; graph LR A--&gt;B B--&gt;C C--&gt;A D--&gt;C &lt;/div&gt; &lt;/body&gt; &lt;/html&gt; ``` ## API usage The main idea with the API is to be able to call a render function with graph defintion as a string. The render function will render the graph and call a callback with the resulting svg code. With this approach it is up to the site creator to fetch the graph definition from the site, perhaps from a textarea, render it and place the graph somewhere in the site. To do this, include mermaidAPI on your web website instead of mermaid.js. The example below show an outline of how this could be used. The example just logs the resulting svg to the javascript console. ``` &lt;script src=&quot;mermaidAPI.js&quot;&gt;&lt;/script&gt; &lt;script&gt; mermaidAPI.initialize({ startOnLoad:false }); $(function(){ // Example of using the API var element = document.querySelector(\"#graphDiv\"); var insertSvg = function(svgCode, bindFunctions){ element.innerHTML = svgCode; }; var graphDefinition = 'graph TB\\na-->b'; var graph = mermaidAPI.render('graphDiv', graphDefinition, insertSvg); }); &lt;/script&gt; ``` ## Sample of API usage together with browserify ``` $ = require('jquery'); mermaidAPI = require('mermaid').mermaidAPI; mermaidAPI.initialize({ startOnLoad:false }); $(function(){ var graphDefinition = 'graph TB\\na-->b'; var cb = function(html){ console.log(html); } mermaidAPI.render('id1',graphDefinition,cb); }); ``` ### Binding events Sometimes the generated graph also has defined interactions like tooltip and click events. When using the API one must add those events after the graph has been inserted into the DOM. The example code below is an extract of wheat mermaid does when using the API. The example show how it is possible to bind events to a svg when using the API for rendering. ``` var insertSvg = function(svgCode, bindFunctions){ element.innerHTML = svgCode; if(typeof callback !== 'undefined'){ callback(id); } bindFunctions(element); }; var id = 'theGraph'; mermaidAPI.render(id,txt,insertSvg, element); ``` 1. The graph is generated using the render call. 2. After generation the render function calls the provided callback function, in this case its called insertSvg. 3. The callback function is called with two parameters, the svg code of the generated graph and a function. This function binds events to the svg **after** it is inserted into the DOM. 4. Insert the svg code into the DOM for presentation 5. Call the binding function that bainds the events ## Example of a marked renderer This is the renderer used for transforming the documentation from markdown to html with mermaid diagrams in the html. ``` var renderer = new marked.Renderer(); renderer.code = function (code, language) { if(code.match(/^sequenceDiagram/)||code.match(/^graph/)){ return '&lt;div class=\"mermaid\">'+code+'&lt;/div>'; } else{ return '&lt;pre>&lt;code>'+code+'&lt;/code>&lt;/pre>'; } }; ``` Another example in coffeescript that also includes the mermaid script tag into the generated markup. ``` marked = require &#39;marked&#39; module.exports = (options) -&gt; hasMermaid = false renderer = new marked.Renderer() renderer.defaultCode = renderer.code renderer.code = (code, language) -&gt; if language is &#39;mermaid&#39; html = &#39;&#39; if not hasMermaid hasMermaid = true html += &#39;&amp;ltscript src=&quot;&#39;+options.mermaidPath+&#39;&quot;&gt;&lt;/script&gt;&#39; html + &#39;&amp;ltdiv class=&quot;mermaid&quot;&gt;&#39;+code+&#39;&lt;/div&gt;&#39; else @defaultCode(code, language) renderer ``` ## Advanced usage **Error handling** When the parser encounters invalid syntax the **mermaid.parseError** function is called. It is possible to override this function in order to handle the error in an application specific way. **Parsing text without rendering** It is also possible to validate the syntax before rendering in order to streamline the user experience. The function **mermaid.parse(txt)** takes a text string as an argument and returns true if the text is syntactically correct and false if it is not. The parseError function will be called when the parse function returns false. The code-example below in meta code illustrates how this could work: ```js mermaid.parseError = function(err,hash){ displayErrorInGui(err); }; var textFieldUpdated = function(){ var textStr = getTextFromFormField('code'); if(mermaid.parse(textStr)){ reRender(textStr) } }; bindEventHandler('change', 'code', textFieldUpdated); ``` # Configuration Mermaid takes a number of options which lets you tweak the rendering of the diagrams. Currently there are three ways of setting the options in mermaid. 1. Instantiation of the configuration using the initialize call 2. *Using the global mermaid object* - deprecated 3. *using the global mermaid_config object* - deprecated 4. Instantiation of the configuration using the **mermaid.init** call The list above has two ways to many of doing this. Three are deprecated and will eventually be removed. The list of configuration objects are described [in the mermaidAPI documentation](http://knsv.github.io/mermaid/index.html#configuration28). ## Using the mermaidAPI.initialize/mermaid.initialize call The future proof way of setting the configuration is by using the initialization call to mermaid or mermaidAPi depending on what kind of integration you use. ``` &lt;script src=&quot;../dist/mermaid.js&quot;&gt;&lt;/script&gt; &lt;script&gt; var config = { startOnLoad:true, flowchart:{ useMaxWidth:false, htmlLabels:true } }; mermaid.initialize(config); &lt;/script&gt; ``` This is the preferred way of configuring mermaid. ## Using the mermaid object Is it possible to set some configuration via the mermaid object. The two parameters that are supported using this approach are: * mermaid.startOnLoad * mermaid.htmlLabels ``` mermaid.startOnLoad = true; ``` This way of setting the configuration is deprecated instead the preferred way of is to use the initialize method. This functionality is only kept for not breaking existing integrations ## Using the mermaid_config Is it possible to set some configuration via the mermaid object. The two parameters that are supported using this approach are: * mermaid_config.startOnLoad * mermaid_config.htmlLabels ``` mermaid_config.startOnLoad = true; ``` This way of setting the configuration is deprecated instead the preferred way of is to use the initialize method. This functionality is only kept for not breaking existing integrations ## Using the mermaid.init call Is it possible to set some configuration via the mermaid object. The two parameters that are supported using this approach are: * mermaid_config.startOnLoad * mermaid_config.htmlLabels ``` mermaid_config.startOnLoad = true; ``` This way of setting the configuration is deprecated instead the preferred way of is to use the initialize method. This functionality is only kept for not breaking existing integrations",
    "tags": "",
    "url": "/peripheral_brain/javascript/mermaid-7.0.0/docs/content/usage.html"
  },{
    "title": "Antibiotic Dosing Parameters",
    "text": "Generic Loading/Maintenance Doses Drug Loading Dose Maintenance Dose (Normal Renal Fx) Gentamicin / Tobramycin 2-2.5 mg/kg 1.5-2 mg/kg q8-12hr * Amikacin 7.5 mg/kg 5-7.5 mg/kg q12hr * Vancomycin 25-30 mg/kg 15-20 mg/kg q8-12hr * (total body weight) Target Concentrations Gentamicin (Gram Negative) / Tobramycin Infection Type Peak (mg/L) Trough (mg/L) Moderate (UTIs) 4-6 ≤ 1 Moderate-Severe (Osteomyeltitis, pyelonephritis, soft-tissue infections) 6-8 ≤ 1 Severe (bacteremia, pneumonia, life-threatening infections) 8-10 ≤ 1 Gentamicin (Gram Positive) Peak: 3-5 mg/L Trough: ≤ 1 mg/L Used in combination with cell-wall active agents such as nafcillin, vancomycin, or ampicillin Amikacin Infection Type Peak (mg/L) Trough (mg/L) Moderate (UTIs) 20-25 4-8 Moderate-Severe (Osteomyeltitis, pyelonephritis, soft-tissue infections) 25-30 4-8 Severe (bacteremia, pneumonia, life-threatening infections) 25-30 4-8 Vancomycin Peak: 30-40 mg/L Trough: 10-15 mg/L (15-20 in endocarditis, osteomyelitis, meningitis, MRSA, and pneumonia) Vd: 0.6-0.7 (0.4-1) L/kg AUC0-24 / MIC = 400 AUC &gt; 700 =&gt; Increased risk of nephrotoxicity NTE 15 mg/min due to risk of Red Man Syndrome CrCl Approximate Dosing Interval (hr) 120 12 100 12-18 80 18 60 24 40 36 30 48 20 60 10 TDM Dialysis Random monitoring q3-4d and adjust Extended Interval Dosing of Aminoglycosides Use IBW if TBW &lt; 1.3 * IBW or AdjBW if TBW ≥ 1.3 * IBW Gentamicin / Tobramycin: 5-7 mg/kg, target peak of 15-20 mg/L Amikacin: 15-25 mg/kg, target peak of 50-60 mg/L Trough should be undetectable Hartford Nomogram Target Max of 20 mg/L (MIC of 2 mg/L targeting 10:1) 7 mg/kg over 1 hour (gent / tob) or 15 mg/kg (amikacin) Obtain a value 6-14hr after the start of the infusion on day 5 CrCl Interval &gt; 60 q24h 40-60 q36h 20-39 q48h &lt; 20 Use traditional *Nomogram for gent/tob; if using amikacin, divide concentration by 2 then proceed as normal",
    "tags": "",
    "url": "/peripheral_brain/calculators/abxDosingParameters.html"
  },{
    "title": "Acid-Base Analysis",
    "text": "pH paCO2 (mmHg) Bicarb (mEq/L) Base Deficit Calculated Other: Na (mEq/L) Cl (mEq/L) Lactate (mmol/L) Albumin (g/dL) Glucose (mg/dL) BUN (mg/dL) EtOH (mg/dL) Osmolality (mOsm/L) Basic Analysis pH Evaluation Pulmonary Evaluation Bicarb Evaluation Qualitative Acid-Base SID SID Evaluation Calculated Base Deficit Strong Ion Gap Strong Ion Gap Evaluation Compensation to... Chronic Resp Decrease in SID: Metabolic Acidosis Decrease in paCO2: Metabolic Alkalosis Increase in paCO2: Osmolarity Osm Osm Gap Note: All compensations will be calculated regardless of appropriate use. See the EM-Crit Acid-Base Evaluation Sheet for descriptions of these processes, as well as DDX for each Acid-Base Disorder",
    "tags": "",
    "url": "/peripheral_brain/calculators/acidBase.html"
  },{
    "title": "Aminoglycoside Initial Dosing",
    "text": "Height (in) Weight (kg) Age (yrs) SCr (mg/dL) Sex Male Female Race African American Other CrCl (mL/min) CKD-Epi CG-CrCl Other: Low Vd (L/kg) High Vd (L/kg) Volume (L) Desired Peak (mg/L) Desired Trough (mg/L) Infusion Time (hr) Max-Peak Interval (hr) Dosing Interval (hr) MD (mg) Kidney Function CG-CrCl mL/min Weight Used for CG CKD-Epi (mL/min/(1.73 m^2)) CKD-Epi (mL/min) Pharmacokinetics k hr^-1 Half-Life hr Low Vd L High Vd L Dosing Interval hr Mainenance Dose mg Double Check MD mg Tau hr Cmax mg/L Cpk mg/L Cmin mg/L",
    "tags": "",
    "url": "/peripheral_brain/calculators/aminoglycosideInitial.html"
  },{
    "title": "Aminoglycoside Peak-Trough Dosing Calculator",
    "text": "Current Patient Values Dose (mg) Pt Peak (mg/L) Pt Trough (mg/L) Current Dosing Interval (hr) Current Infusion Time (hr) Max-Peak Interval (hr) Trough-Min Interval (hr) Desired Values Desired Peak (mg/L) Desired Trough (mg/L) Infusion Time (hr) Max-Peak Interval (hr) Dosing Interval (hr) MD (mg) Pharmacokinetics k hr^-1 Half-Life hr Pt Vd L Dosing Interval hr Mainenance Dose mg Double Check MD mg Tau hr Cmax mg/L Cpk mg/L Cmin mg/L Next Dose Delay* Delay hr *This value represents the minimum time elapsed between the last peak and the next administration to garuntee the drug has decreased below the desired trough concentration",
    "tags": "",
    "url": "/peripheral_brain/calculators/aminoglycosidePeakTrough.html"
  },{
    "title": "Common Patient Calculations",
    "text": "Height (in) Weight (kg) Age (yrs) SCr (mg/dL) Sex Male Female Race African American Other Weights IBW kg ABW kg LBW kg BSA m^2 Kidney Function CG-CrCl mL/min Weight Used for CG CKD-Epi (mL/min/(1.73 m^2)) CKD-Epi (mL/min)",
    "tags": "",
    "url": "/peripheral_brain/calculators/commonCalcs.html"
  },{
    "title": "Vancomycin Initial Dosing",
    "text": "Height (in) Weight (kg) Age (yrs) SCr (mg/dL) Sex Male Female Race African American Other CrCl (mL/min) CKD-Epi CG-CrCl Other: MIC (mg/L) Low Vd (L/kg) High Vd (L/kg) Volume (L) Desired Peak (mg/L) Desired Trough (mg/L) Infusion Time (hr) Max-Peak Interval (hr) Dosing Interval (hr) MD (mg) Kidney Function CG-CrCl mL/min Weight Used for CG CKD-Epi (mL/min/(1.73 m^2)) CKD-Epi (mL/min) Pharmacokinetics k hr^-1 Half-Life hr Low Vd L High Vd L Dosing Interval hr Mainenance Dose mg Double Check MD mg Tau hr Cmax mg/L Cpk mg/L Cmin mg/L AUC0-24hr mg*hr/L AUC0-24hr / MIC Note: Maximum Infusion Rate of 15mg/min",
    "tags": "",
    "url": "/peripheral_brain/calculators/vancInitial.html"
  },{
    "title": "Vancomycin Peak-Trough Dosing",
    "text": "Current Patient Values Dose (mg) Pt Peak (mg/L) Pt Trough (mg/L) Current Dosing Interval (hr) Current Infusion Time (hr) Max-Peak Interval (hr) Trough-Min Interval (hr) MIC (mg/L) Desired Values Desired Peak (mg/L) Desired Trough (mg/L) Infusion Time (hr) Max-Peak Interval (hr) Dosing Interval (hr) MD (mg) Pharmacokinetics k hr^-1 Half-Life hr Pt Vd L Dosing Interval hr Mainenance Dose mg Double Check MD mg Tau hr Cmax mg/L Cpk mg/L Cmin mg/L AUC0-24hr mg*hr/L AUC0-24hr / MIC Note: Maximum Infusion Rate of 15mg/min",
    "tags": "",
    "url": "/peripheral_brain/calculators/vancPeakTrough.html"
  },{
    "title": "The 1st 5 Minutes",
    "text": "ACS MONA Morphine 2-4mg IV q5-30min in increments of 2-8mg PRN BP and RR after each bolus Can consider meperidine or other opiod D/C all NSAIDs and avoid all NSAIDs during admission O2 to sat of 95% if &lt; 90% on presentation SL NTG 0.4mg q5min x3, if non-responsive start IV NTG 5-10mcg/min to 75-100mcg/min (Max 200, consider 1-2min bolus of 400mcg/min to load) Verify NO PDEIs w/i 24-36hr IV Contraindicated w/ SBP &lt; 90; &gt; 30 mmHg change from baseline; Bradycardia or Tachycardia; Suspected RV Infarction Monitor BP and HR q2h while on IV ASA 325mg Chewed and Swallowed on presentation Consider anxiolytics to decrease HR and demand Consider PCI for STEMI Consult ACS for further management Stroke Labs Conduct NIHSS (National Institutes of Health Stroke Scale) Head CT to r/o hemorrhagic stroke Monitor BP / O2Sat BG BMP CBC INR / aPTT EKG Echo Pt is NPO until swallow study conducted Initial Therapies Manage BG if abnormal Hypoglycemia can result in stroke SSx Hyperglycemia above 180 mg/dL can result in higher morbidity / mortality Consider thrombolytics for ischemic strokes (must r/o hemorrhagic) Manage HTN to &lt; 220/120 for non-thrombolytic pts, &lt; 180/105 for thrombolysis IV antihypertensives warranted, do not lower BP excessively, as elevated BP may help perfuse partially occluded areas Agressive BP control can limit stroke recurrence, long-term neuro deficits, an decrease risk of cerebral edema; however concern from above usually wins, attempt to balance (i.e 150s instead of 170s or 110s) Thrombolysis Dosing Must satisfy inclusion / exclusion criteria below 0.9 mg/kg NTE 90mg Total dose 10% (0.09 mg/kg) IVPB over 1min 90% (0.81 mg/kg) IV over 60min Give w/i 60min of arrival Keep BP &lt; 180/105 Monitor q15min x2h then q30min x 6h then q1h x16hr Can begin to lower to outpt goal after 24h Avoid all antiplatelets and anticoagulants for 24hr post-admin SEs Bleeding Stroke Conversion Cerebral Edema Inclusion Criteria Ischemic stroke confirmed by imaging &lt; 3hrs from SSx onset Extended interval available, see below Some evidence for imaging-based determination of thrombolysis eligbility here, but not currently in guidelines ≥ 18yo Exclusion Criteria Evidence of active internal bleed Hx of intracranial hemorrhage Previous stroke or head trauma in less than 3mo GI or GU hemorrhage in ≤ 21d Major surgery in ≤ 14d MI in ≤ 3mo BP &gt; 185/110 at administration time BG &lt; 50 mg/dL Plt &lt; 100k Current anticoag w/ INR &gt; 1.7 or aPTT &gt; 45s NOACs CI tPA Reversible exclusion criteria Extended tPA Window &lt; 4.5hrs after SSx onset Add the following to the exclusion criteria Age ≥ 80 Hx of Stroke w/ DM Any recent anticoag use NIHSS &gt; 25 BP Control Use common IV antihypertensives discussed in HTN Crisis section Labetalol 10-20mg IVPB q10-20min NTE 300mg Nicardipine 5mg/hr IV titrated q5min NTE 15 mg/hr Nitroprusside 0.5-10 mcg/kg/min titrated (preferable if DBP &gt; 140) Transfusion for Severe Acute Anemia Criteria Acutely Symptomatic Hgb &lt; 8 (some argue 7) Admin PRBCs Type and cross before admin 1 U &amp;approx; 300 mL &amp;approx; Δ 1 g/dL Hgb Consider activation of massive transfusion protocol Hemorrhaging / trauma pts may require infusions of FFP and Plt as well to sustain coagulation, strongly consider before using large volumes of crystalloid Pts refusing transfusion can be given high dose iron, B12, and Epo, look up protocol Complications Iron Overload Infection (HIV etc, rare) Hyperviscosity syndrome Alloimmunization Volume overload Transfusion reactions",
    "tags": "",
    "url": "/peripheral_brain/firstFive"
  },{
    "title": "Formulas",
    "text": "Dosing and Body Weights Acid-Base Nitrogen Balance Fluids and Electrolytes Anticoagulation EKG Interpretation Pharmacokinetics General PK 1-Compartment Model",
    "tags": "",
    "url": "/peripheral_brain/formulas"
  },{
    "title": "Lab Values",
    "text": "ABG pH / paCO2 / paO2 / [HCO3]- / O2 Sat Lab Low High Units pH 7.35 7.45 n/a paCO2 35 45 mmHg paO2 80 100 mmHg HCO3- 22 26 mEq/L O2 Sat 95% 100% % Saturation Electrolytes Lab Low High Units pH 7.35 7.45 n/a Na+ 135 145 mEq/L Cl- 95 105 mEq/L K+ 3.5 5 mEq/L Ca2+ 8.5 10.5 mg/dL Ionized Ca2+ 4.6 5.1 mg/dL HCO3- 22 26 mEq/L Mg2+ 1.5 2.5 mg/dL PO43- 2.5 4.5 mg/dL Osm 275 290 mOsm/L Anion Gap 3 11 mEq/L Chem7 Na K Cl Bicarb BUN SCr Gluc Hematology WBC Plt Hgb Hct Lab Low High Unit Hgb (M) 13.5 17.5 g/dL Hgb (F) 12 16 g/dL Hct (M) 41 53 % Hct (F) 36 46 % RBC (M) 4.5 5.9 M/mcL RBC (F) 4.1 5.1 M/mcL MCV 80 100 fL RDW 11 15 % Folate 1.8 16 ng/mL B12 100 900 pg/mL Cells Low % High % Segmented 45 75 Bands 3 5 Lymphocytes 20 40 Monocytes 2 8 Eosinophils 0 4 Basophils 2 2 Lab Low High Unit Ferritin 10 20 mcg/L Serum Iron 60 150 mcg/dL Transferrin 20 50 % TIBC 250 400 mcg/dL Anticoagulation Monitoring Test Evaluating Low High Units Platelet Count Bone Marrow 150 450 k/mm3 PT Extrinsic Pathway 12 14 sec INR Extrinsic Pathway - 1.1 n/a aPTT Intrinsic Pathway 26 33 sec EKG Normal Values Measure Interval (ms) PR Interval 120-200 QRS 80-120 QT* 380-460 QTc (Male)* 360-470 QTc (Female)* 360-480 *High risk of Torsades w/ QTc ≥500ms",
    "tags": "",
    "url": "/peripheral_brain/lab_values"
  },{
    "title": "Sources",
    "text": "Cardiology ACS AHA NSTE-ACS Guidelines 2014 [^amsterdam2014]: Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes. Journal of the American College of Cardiology. 2014;64(24):e139-e228. doi:10.1016/j.jacc.2014.09.017 AHA STEMI Guidelines [^ogara2013]: O’Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction. *Journal of the American College of Cardiology*. 2013;61(4):e78-e140. doi:[10.1016/j.jacc.2012.11.019](https://doi.org/10.1016/j.jacc.2012.11.019) Benign Early Repol vs Subtle LAD STEMI (4-variable) [^driver2017]: Driver BE, Khalil A, Henry T, Kazmi F, Adil A, Smith SW. A new 4-variable formula to differentiate normal variant ST segment elevation in V2-V4 (early repolarization) from subtle left anterior descending coronary occlusion - Adding QRS amplitude of V2 improves the model. *Journal of Electrocardiology*. 2017;50(5):561-569. doi:[10.1016/j.jelectrocard.2017.04.005](https://doi.org/10.1016/j.jelectrocard.2017.04.005) DAPT Duration in CAD [^levine2016]: Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease. *Journal of the American College of Cardiology*. 2016;68(10):1082-1115. doi:[10.1016/j.jacc.2016.03.513](https://doi.org/10.1016/j.jacc.2016.03.513) LBBB vs STEMI [^smith2012]: Smith SW, Dodd KW, Henry TD, Dvorak DM, Pearce LA. Diagnosis of ST-Elevation Myocardial Infarction in the Presence of Left Bundle Branch Block With the ST-Elevation to S-Wave Ratio in a Modified Sgarbossa Rule. *Annals of Emergency Medicine*. 2012;60(6):766-776. doi:[10.1016/j.annemergmed.2012.07.119](https://doi.org/10.1016/j.annemergmed.2012.07.119) Third Universal MI Definition [^thygesen]: Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD. Third Universal Definition of Myocardial Infarction. :16. STEMI PCI Update [^levine2015]: Levine GN, Bates ER, Blankenship JC, et al. 2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction. *Journal of the American College of Cardiology*. 2016;67(10):1235-1250. doi:[10.1016/j.jacc.2015.10.005](https://doi.org/10.1016/j.jacc.2015.10.005) HTN AHA HTN Guidelines [^whelton2018]: Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. *Journal of the American College of Cardiology*. 2018;71(19):e127-e248. doi:[10.1016/j.jacc.2017.11.006](https://doi.org/10.1016/j.jacc.2017.11.006) ACCP HTN Emergency [^benken2018]: Benken ST. ACCP Hypertensive Emergencies. 2018. Available at: https://www.accp.com/docs/bookstore/ccsap/ccsap2018b1_sample.pdf VTE VTE Treatment Guidelines [^kearon2016]: Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease. Chest. 2016;149(2):315-352. doi:[10.1016/j.chest.2015.11.026](https://doi.org/10.1016/j.chest.2015.11.026) VTE Prophylaxis [^gould2012]: Gould MK, Garcia DA, Wren SM, et al. Prevention of VTE in Nonorthopedic Surgical Patients. Chest. 2012;141(2):e227S-e277S. doi:[10.1378/chest.11-2297](https://doi.org/10.1378/chest.11-2297) CHF [^yancy2013]: Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2013;128(16). doi:[10.1161/CIR.0b013e31829e8776](https://doi.org/10.1161/CIR.0b013e31829e8776) [^yancy2017]: Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure. *Journal of the American College of Cardiology*. 2017;70(6):776-803. doi:[10.1016/j.jacc.2017.04.025 HLD [^grundy2018]: Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. *Journal of the American College of Cardiology*. November 2018. doi:[10.1016/j.jacc.2018.11.003](https://doi.org/10.1016/j.jacc.2018.11.003) [^jacobson2015]: Jacobson TA, Ito MK, Maki KC, et al. National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1—Full Report. *Journal of Clinical Lipidology*. 2015;9(2):129-169. doi:[10.1016/j.jacl.2015.02.003](https://doi.org/10.1016/j.jacl.2015.02.003) [^jentzer2015]: Jentzer JC, Coons JC, Link CB, Schmidhofer M. Pharmacotherapy Update on the Use of Vasopressors and Inotropes in the Intensive Care Unit. *Journal of Cardiovascular Pharmacology and Therapeutics*. 2015;20(3):249-260. doi:[10.1177/1074248414559838](https://doi.org/10.1177/1074248414559838) Critical Care Hypotension Management Push-Dose Pressors [^weingart2015]: Weingart S. Push-dose pressors for immediate blood pressure control. *Clinical and Experimental Emergency Medicine*. 2015;2(2):131-132. doi:[10.15441/ceem.15.010](https://doi.org/10.15441/ceem.15.010) [^hollenberg2011]: Hollenberg SM. Vasoactive Drugs in Circulatory Shock. American Journal of Respiratory and Critical Care Medicine. 2011;183(7):847-855. doi:[10.1164/rccm.201006-0972CI](https://doi.org/10.1164/rccm.201006-0972CI) [^jentzer2015]: Jentzer JC, Coons JC, Link CB, Schmidhofer M. Pharmacotherapy Update on the Use of Vasopressors and Inotropes in the Intensive Care Unit. Journal of Cardiovascular Pharmacology and Therapeutics. 2015;20(3):249-260. doi:[10.1177/1074248414559838](https://doi.org/10.1177/1074248414559838) [^overgaard2008]: Overgaard CB, Džavík V. Inotropes and Vasopressors: Review of Physiology and Clinical Use in Cardiovascular Disease. Circulation. 2008;118(10):1047-1056. doi:[10.1161/CIRCULATIONAHA.107.728840](https://doi.org/10.1161/CIRCULATIONAHA.107.728840) Stress Ulcer Prophylaxis [^barletta2016]: Barletta JF, Bruno JJ, Buckley MS, Cook DJ. Stress Ulcer Prophylaxis: *Critical Care Medicine*. 2016;44(7):1395-1405. doi:[10.1097/CCM.0000000000001872](https://doi.org/10.1097/CCM.0000000000001872) [^erstad1999]: Erstad BL, et al. ASHP Therapeutic Guidelines on Stress Ulcer Prophylaxis. 1999. ID Vancomycin Dosing Optimizing Vancomycin Dosing [^deryke2009]: Deryke CA, Alexander DP. Optimizing Vancomycin Dosing through Pharmacodynamic Assessment Targeting Area under the Concentration-Time Curve/Minimum Inhibitory Concentration. *Hospital Pharmacy*. 2009;44(9):751-765. doi:[10.1310/hpj4409-751](https://doi.org/10.1310/hpj4409-751) Vancomycin PK in Renal Dysfunction [^matzkel1984]: Matzke GR, McGory RW, Halstenson CE, Keane WF. Pharmacokinetics of vancomycin in patients with various degrees of renal function. *Antimicrobial Agents and Chemotherapy*. 1984;25(4):433-437. doi:[10.1128/AAC.25.4.433](https://doi.org/10.1128/AAC.25.4.433) ASHP Vancomycin Monitoring Recommendations [^rybak2009]: Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. *American Journal of Health-System Pharmacy*. 2009;66(1):82-98. doi:[10.2146/ajhp080434](https://doi.org/10.2146/ajhp080434) Aminoglycoside Dosing Stanford Health System Aminoglycoside Dosing Recommendations [^mui2017]: Mui, E. Stanford Health Care Aminoglycoside Dosing Guideline. 2017. [Link](http://med.stanford.edu/bugsanddrugs/dosing-protocols/_jcr_content/main/panel_builder/panel_0/download_2/file.res/Aminoglycoside%20Dosing%20Guide%202017-08-23.pdf) Extended Interval Aminoglycosides [^nicolau1995]: Nicolau DP, Freeman CD, Belliveau PP, Nightingale CH, Ross JW, Quintiliani R. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. *Antimicrobial Agents and Chemotherapy*. 1995;39(3):650-655. doi:[10.1128/AAC.39.3.650](https://doi.org/10.1128/AAC.39.3.650) Pulmononolgy GOLD COPD Guidelines 2018 [^goldCOPD]: Vogelmeier C, Agusti A, *et al*. Global Initiative for Chronic Obstructive Lung Disease. [Available Here](https://goldcopd.org/wp-content/uploads/2018/02/WMS-GOLD-2018-Feb-Final-to-print-v2.pdf) Textbooks Pharmacology DiPiro Pharmacotherapy [^dipiro]: DiPiro JT, ed. *Pharmacotherapy: A Pathophysiologic Approach*. Tenth edition. New York: McGraw-Hill Education; 2017. Emergency Medicine Tintinalli’s [^tintinalli]: Tintinalli JE, Stapczynski JS, Ma OJ, Cline D, Meckler GD, Yealy DM, eds. *Tintinalli’s Emergency Medicine: A Comprehensive Study Guide*. Eight edition. New York: McGraw-Hill Education; 2016. Websites Drug Resources Lexicomp [^lexi]: Lexi-Drugs. Lexicomp. Wolters Kluwer Health, Inc. Riverwoods, IL. Available at: [http://online.lexi.com](http://online.lexi.com).",
    "tags": "",
    "url": "/peripheral_brain/sources"
  },{
    "title": "ACS",
    "text": "Dx 1,2 ECG w/i 10min of arrival, then Q15-30min x1hr if not initially diagnositc CXR / Chest CT to r/o thoracic aortic aneurysm / dissection, PE, pneumothorax, PNA, etc Serial cTn ASAP then Q3-6hr TIMI Risk Score for all NSTE-ACS (1pt for each below 3) ≥ 65yo Prior Coronary Stenosis ≥ 50% ST Depression ≥ 0.5mm ≥ 2 Anginal events w/i 24hrs ASA use w/i 7d (+) Cardiac Enzymes ≥ 3 CAD risk factors Smoking HTN Dyslipidemia DM FHx of premature CAD or Sudden Cardiac Death GRACE Risk Score STEMI Dx Criteria ESC/ACC/AHA 4,5 ST Elevation in 2 anatomically contiguous leads ≥ 0.1mV at the J-point except V2-V3 (use the following in V2-V3 Men ≥ 40: ≥ 0.2 mV Men &lt; 40: ≥ 0.25 mV Women: ≥ 0.15 mV New horizontal / down-sloping ST-depression in 2 contiguous leads ≥ 0.05 mV T-wave Inversion in 2 contiguous leads ≥ 0.1 mV with prominent R waves or Definitively new LBBB In the presence of existing LBBB consider Smith-Modified Sgarbossa Criteria 6 ≥ 3 points ⇒ 98% Likelihood of MI ST-elevation ≥1 mm in a lead with upward QRS complex (concordant) - 5 points ST-depression ≥1 mm in lead V1, V2, or V3 - 3 points - 2 points New LAFB and RBBB is concerning for LAD occlusion ST-elevation with ST-depression in aVL is highly suspicious for STEMI Local ST-depression in V1-V4 is suspicious for isolated posterior infarct ST-elevation in aVL with depression in III is suspicious for high lateral MI Subtle LAD occlusion vs EBR 7 0.052 x QTc - 0.151 x (QRS voltage in V2) - 0.268 x (R-wave amplitude in V4) + 1.062 x (ST-elevation 60ms after J-point in V3) ≥ 18.2 ⇒ 88.8% sensitive, 94.7% specific ≥ 17.75 ⇒ 90.2% sensitive, 90.6% specific Infarction EKG Patterns 1 Location Electrocardiographic Findings Artery Anteroseptal ST-segment elevations in V1, V2, and possibly, V3 LAD Anterior ST-segment elevations in V1, V2, V3, and V4 LAD Anterolateral ST-segment elevations in V1–V6, I, and aVL LAD or LCX Lateral ST-segment elevations in I and aVL LCX Inferior ST-segment elevations in II, III, and aVF RCA or RCX (20%) Inferolateral ST-segment elevations in II, III, aVF, and V5 and V6 LCX or RCA or RCX True posterior Initial R waves in V1 and V2 &gt; 0.04 s and R/S ratio ≥ 1 LCX Right ventricular ST-segment elevations in II, III, and aVF and ST elevation in right-side V4 RCA Tx 1,4 Empiric ASA 325mg (chew &amp; swallow) for all pts at risk for AMI w/o CIs Nitrates Nitro 0.4mg SL Q5min x3 doses Nitro IV Start at 10 mcg/min, titrate to 10% reduction in MAP if normotensive, 30% reduction in MAP if hypertensive Avoid in RV infarction (d/t dependance on preload for maintaining CO) CI w/ PDE-5 Inhibitors w/i 24hr (48hr if Tadalafil) Supplemental O2 PRN for O2Sat &lt; 90% Morphine 2-5mg IV Q5-15min PRN is the preferred method of pain control d/t vasodilatory properties STEMI 1,4 PCI Management PCI w/i 90min if PCI at facility or w/i 120min for transfer if... &lt;12hr from SSx onset &lt;12h and CI to fibrinolytics regardless of time limits above Cardiogenic shock or acute HF regardless of SSx onset Potentially if SSx for 12-24hr P2Y12 Inhibitor Clopidogrel 600mg load then 75mg PO QD x1yr Prasugrel 60mg load then 10mg PO QD x1yr (CI w/ prior stroke) Ticagrelor 180mg load then 90mg PO BID x1yr (ASA NTE 100mg w/ ticagrelor) Anticoag UFH w/ GP IIb/IIIa: 50-70 U/kg bolus targeting aPTT 200-250s UFH w/o GP IIB/IIIA: 70-100 U/kg bolus targeting aPTT 250-350s Bivalirudin 0.75 mg/kg bolus then 1.75 mg/kg/hr Reduce to 1 mg/kg/hr if CrCl &lt; 30 Preferred over UFH w/ GP IIb/IIIa if high bleed risk GP IIb/IIIa Inhibitors Only for select patients Abciximab 0.25 mg/kg IVB then 0.125 mcg/kg/min NTE 10 mcg/min Tirofiban 25 mcg/kg IVB then 0.15 mcg/kg/min CrCl &lt; 30: Reduce rate by 50% Eptifibatide 180 mcg/kg IVB then 2 mcg/kg/min then 180 mcg/kg IVB 10min after 1st IVB CrCl &lt; 50: Reduce rate by 50% Avoid in pts on HD Medical Management Thrombolytics preferably w/i 30min, should be w/i 1-2hr of presentation if PCI not indicated from above (see dosing below) SSx &lt; 12h Potentially if SSx for 12-24hr Check All CIs to thrombolytics closely Clopidogrel ≤ 75yo: 300mg load then 75mg QD x14d-1yr &gt; 75yo: 75mg QD x14d-1yr (no load) Anticoag UFH Target aPTT 1.5-2x ULN (⇒ 50-70s) x48hr or until revascularization 60 U/kg IVB NTE 4000 U then 12 U/kg/hr NTE 1000 U/hr initially titrated to above goal Enoxaparin &lt; 75yo: 30mg IV then 15min later 1 mg/kg SubQ Q12H NTE 100mg for the 1st 2 doses ≥ 75yo: 0.75 mg/kg SubQ Q12H NTE 75mg for the 1st 2 doses CrCl &lt; 30: 1 mg/kg Q24H instead For duration of stay NTE 8d or until revascularization (unless other indication arises) Fondaparinux 2.5mg IVB then 2.5mg SubQ QD starting the next day CI if CrCl &lt; 30 For duration of stay NTE 8d or until revascularization (unless other indication arises) NSTE-ACS 2 Choosing Strategies Early Invasive w/i 2hr Refractory Angina Hemodynamic / Electrical Instability Sustained VT / VF SSx of HF or mitral regurgitation Stable pts w/ increased risk of clinical events Early-invasive (&lt; 24hr) is better than delayed-invasive if intermediate-high risk Ischemia Guided Extensive co-morbidities significantly increasing the risk of catheterization Acute chest-pain that has a low likelihood of being ACS who are (-) troponin, esp. in women TIMI 0-1 or Grace &lt; 109 Pt / clinician preference in pts w/o high-risk features Early Invasive w/i 24hr None of above but GRACE &gt; 140 Changes in Troponin New ST depression Delayed Invasive (25-72hr) None of above but DM CrCl &lt; 60 LVEF &lt; 40% PCI w/i 6mo Prior CABG GRACE 109-140 or TIMI ≥ 2 Early postinfarction angina Ischemia Guided Strategy P2Y12 Inhibitor Clopidogrel 600mg load then 75mg PO QD x1yr Ticagrelor 180mg load then 90mg PO BID x1yr (ASA NTE 100mg w/ ticagrelor, preferred) Anticoag UFH 60 U/kg load NTE 4000 U then 12 U/kg/h NTE 1000 U/hr titrated to therapeutic aPTT x48hr or until PCI Enoxaparin 30mg mg/kg IV loading dose then 1 mg/kg Q12H w/ typical renal adjustments for duration of stay or until PCI Fondaparinux 2.5mg SubQ QD for duration of stay or until PCI Early-Invasive Strategy P2Y12 Inhibitor Clopidogrel 600mg load then 75mg PO QD x1yr Ticagrelor 180mg load then 90mg PO BID x1yr (ASA NTE 100mg w/ ticagrelor, preferred) Anticoag UFH 60 U/kg load NTE 4000 U then 12 U/kg/h NTE 1000 U/hr titrated to therapeutic aPTT x48hr or until PCI Bivalirudin 0.1 mg/kg bolus then 0.25 mg/kg/hr Enoxaparin 30mg mg/kg IV loading dose then 1 mg/kg Q12H w/ typical renal adjustments for duration of stay or until PCI Fondaparinux 2.5mg SubQ QD for duration of stay or until PCI GP IIb/IIIa Inhibitors (high-risk only) Only for select patients Tirofiban 12 mcg/kg IVB then 0.14 mcg/kg/min CrCl &lt; 30: Reduce rate and bolus by 50% Eptifibatide 180 mcg/kg IVB then 2 mcg/kg/min CrCl &lt; 50: Reduce rate by 50% Avoid in pts on HD Thrombolytic Dosing 8 tPA 15mg IVB over 1-2min then 0.75mg/kg IV over 30min NTE 50mg then 0.5 mg/kg IV over 1hr NTE 35mg Total dose NTE 100mg Wt to achieve max dose: 67kg Reteplase 10 Units IV over 2min then 10 Units IV over 2min 30min later Tenecteplase IV bolus over 5 seconds &lt;60 kg: 30 mg ≥ 60 to &lt;70 kg: 35 mg ≥ 70 to &lt;80 kg: 40 mg ≥ 80 to &lt;90 kg: 45 mg ≥ 90 kg: 50 mg Thrombolytic CIs 4 Absolute CIs Any prior ICH Known structural cerebral vascular lesion (e.g., arteriovenous malformation) Known malignant intracranial neoplasm (primary or metastatic) Ischemic stroke within 3 mo EXCEPT acute ischemic stroke within 4.5 h Suspected aortic dissection Active bleeding or bleeding diathesis (excluding menses) Significant closed-head or facial trauma within 3 mo Intracranial or intraspinal surgery within 2 mo Severe uncontrolled hypertension (unresponsive to emergency therapy) For streptokinase, prior treatment within the previous 6 mo Relative CIs History of chronic, severe, poorly controlled hypertension Significant hypertension on presentation (SBP &gt; 􏰁180 mm Hg or DBP &gt; 􏰁110 mm Hg) History of prior ischemic stroke &gt; 􏰁3 mo Dementia Known intracranial pathology not covered in absolute contraindications Traumatic or prolonged ( &gt; 􏰁10 min) CPR Major surgery ( &lt; 􏰂3 wk) Recent (within 2 to 4 wk) internal bleeding Noncompressible vascular punctures Pregnancy Active peptic ulcer Oral anticoagulant therapy Post-ACS Chronic Therapies Beta-blockers in pts w/o CIs ACEIs / ARBs, esp in pts w/ LVEF &lt; 40% High-Intensity Statins NTG SL PRN References Tintinalli JE, Stapczynski JS, Ma OJ, Cline D, Meckler GD, Yealy DM, eds. Tintinalli’s Emergency Medicine: A Comprehensive Study Guide. Eight edition. New York: McGraw-Hill Education; 2016. &#8617; &#8617;2 &#8617;3 &#8617;4 Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes. Journal of the American College of Cardiology. 2014;64(24):e139-e228. doi:10.1016/j.jacc.2014.09.017 &#8617; &#8617;2 DiPiro, JT, ed. Pharmacotherapy: A Pathophysiologic Approach. Tenth edition. New York: McGraw-Hill Education, 2017. &#8617; O’Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction. Journal of the American College of Cardiology. 2013;61(4):e78-e140. doi:10.1016/j.jacc.2012.11.019 &#8617; &#8617;2 &#8617;3 &#8617;4 Thygesen, K, Alpert, JS, Jaffe, AS, Simoons, ML, Chaitman, BR, and White, HD. Third Universal Definition of Myocardial Infarction.16. &#8617; Smith, SW, Dodd, KW, Henry, TD, Dvorak, DM, and Pearce, LA. Diagnosis of ST-Elevation Myocardial Infarction in the Presence of Left Bundle Branch Block With the ST-Elevation to S-Wave Ratio in a Modified Sgarbossa Rule. Annals of Emergency Medicine 2012;60:766–776. &#8617; Driver, BE, Khalil, A, Henry, T, Kazmi, F, Adil, A, and Smith, SW. A New 4-Variable Formula to Differ- entiate Normal Variant ST Segment Elevation in V2-V4 (Early Repolarization) from Subtle Left Anterior Descending Coronary Occlusion - Adding QRS Amplitude of V2 Improves the Model. Journal of Electrocardiology 2017;50:561–569. &#8617; Lexi-Drugs. Lexicomp. Wolters Kluwer Health, Inc. Riverwoods, IL. Available at: http://online.lexi.com. &#8617;",
    "tags": "",
    "url": "/peripheral_brain/diseases/acs.html"
  },{
    "title": "APAP Overdose",
    "text": "Dx1 APAP toxicity usually seen with ingestions of &gt;10g or 200mg/kg in 24hr OR &gt;6g or 150mg/kg QD x2d SSx N/V Anorexia Abd pain HypoK Abnormal LFTs Encephalopathy Jaundice Anuria Workup Serum APAP &gt;4hr post-ingestion for nomogram below Others as indicated Serum ASA Chem7 CBC LFTs SCr / BUN Urine Tox Tx1,2 Use Rumack-Matthew Nomogram if level not available w/i 8hr, treat empirically Activated Charcoal 1g/kg if recent exposure, preferably w/i 1hr, but maybe 3-4hr post-exposure NAC as dosed below if above nomogram line or if &gt;24hr post-exposure w/ level &gt;10 mcg/mL (mg/L) Dosing wt NTE 100kg 100mg/kg IV over 15-60min then 50mg/kg IV over 4hr then 100mg/kg IV over 16hr all in D5W PO therapy also available watch for tinnitus and anaphylaxis Admit consider transplant if AMS, PTT &gt;100, pH &lt; 7.3, or SCr &gt; 3.3 after delayed therapy (&gt;24hr post-exposure) APAP Nomogram1 References Tintinalli JE, Stapczynski JS, Ma OJ, Cline D, Meckler GD, Yealy DM, eds. Tintinalli’s Emergency Medicine: A Comprehensive Study Guide. Eight edition. New York: McGraw-Hill Education; 2016. &#8617; &#8617;2 &#8617;3 Lexi-Drugs. Lexicomp. Wolters Kluwer Health, Inc. Riverwoods, IL. Available at: http://online.lexi.com. &#8617;",
    "tags": "",
    "url": "/peripheral_brain/diseases/apapOverdose.html"
  },{
    "title": "CHF",
    "text": "Dx1 HFrEF: HF w/ LVEF ≤ 40% HFpEF: HF w/ LVEF ≥ 50% &gt; 40% is borderline HFpEF Measure NT-proBNP or BNP if suspicious CXR and Doppler Echo on initial workup Staging / Classification AHA Stages Stage Description A High risk w/o structural heart disease and w/o HF SSx B SHD w/o SSx of HF C SHD w/ current or prior HF SSx D Refractory HF SSx NYHA Classifications Classification Description I No limitations of physical activity d/t SSx II Normal physical activity results in SSx III Mild physical activity results in SSx IV SSx at rest DDx of Dilated Cardiomyopathies Genetic / Familial Obesity DM Hyperthyroidism Acromegaly EtOH Cocaine HER-2 and/or anthracyclines Various other toxins Chronic Tachycardia Myocarditis SLE HIV Other infections Chagas disease Hypersensitivity myocarditis Scleroderma and other rheumatologist conditions Peripartum cardiomyopathy Hemochromatosis and iron overload Amyloidosis Tx (HFrEF)1, 2 Stage A Modify risk factors as appropriate, with emphasis on wt loss, smoking cessation, BP control, HLD control, and DM control Stage B All pts should receive… ACEI (ARB if CI) β-blocker Metoprolol tartrate Bisoprolol Carvedilol Statins (if Hx of ACS or CAD) Other means of BP control PRN Consider spironolactone if HTN is refractory to above agents Consider prophylactic ICD Stage C All pts should receive… ACEI or ARB or ARNI Tolerating ACEI or ARB and able to afford =&gt; transition to ARNI Do not give ARNI w/i 36hr of ACEI or ARB Do not give ARNIs to pts w/ Hx of angioedema Monitor and titrate slowly Q1-2wks β-blocker Metoprolol tartrate Bisoprolol Carvedilol Consider ivabridine if on maximum BB dose, LVEF ≤ 35%, and RHR ≥ 70 Start low and titrate up when SSx of current dose abide Spironolactone CrCl &gt; 30 and K &lt; 5 If LVEF ≤ 35% OR LVEF ≤ 40% w/ HF or DM after MI Consider Hydralazine-Nitrate combos in black pts PRN Diurectics for fluid status control Preferably Loops, with thiazides added for diuretic resistance PRN Additional BP Meds PRN for goal of &lt; 130/80 Consider Digoxin to decrease hospitalizations 0.125-0.25mg QD NTE 0.5-0.75mg QD Goal Plasma Range of 0.5-0.9 ng/mL Avoid CCBs except amlodipine Dosing HF Drug Dosing Drug Initial Dose Max Dose ACEIs Captopril 6.25mg TID 50mg TID Enalapril 2.5mg BID 10-20mg BID Lisinopril 2.5-5mg QD 20-40mg QD ARBs Candesartan 4-8mg QD 32mg QD Losartan 25-50mg QD 50-150mg QD Valsartan 20-40mg BID 160mg BID ARNI Sacubitril/Valsartan 49mg/51mg BID(or 24mg/26mg BID) 97mg/103mg BID If Channel Inhibitor Ivabradine 5mg BID 7.5mg BID Aldosterone Antagonists Spironolactone 12.5-25mg QD 25mg QD or BID Eplerenone 25mg QD 50mg QD β-Blockers Bisoprolol 1.25mg QD 10mg QD Carvedilol 3.125mg BID 50mg BID Carvedilol CR 10mg QD 80mg QD Metoprolol Succinate 12.5-25mg QD 200mg QD ISDN-Hydralazine Combo Pill 20mg/37.5mg TID 40mg/75mg TID Individual Pills 20-30mg/25-50mg TID or QD 40mg TID / 100mg TID HF Diuretic Dosing Drug Initial Dose Max TDD Loops Bumetanide 0.5-1mg QD-BID 10mg Furosemide 20-40mg QD-BID 600mg Torsemide 10-20mg QD 200mg Thiazides Chlorthiazide 250-500mg QD-BID 1000mg Chlorthalidone 12.5-25mg QD 100mg HCTZ 25mg QD or BID 200mg Indapamide 2.5mg QD 5mg Metolazone 2.5mg QD 20mg K-Sparing Amiloride 5mg QD 20mg Spironolactone 12.5-25 QD 50mg Triamterene 50-75mg BID 200mg Stage D Fluid restrict to 1.5-2 L QD Consider milrinone or dobutamine for inotropy Consider LVAD Consider transplant Acute Decompensated HF1, 3 Continue home HF meds unless CI or hemodynamically unstable / failing renal Fx IV diuretics for fluid-overloaded pts Furosemide 40mg, Bumetanide 1-3mg, or Torsemide 10-20mg for naive pts Should give higher doses than home Give vasodilators if pt has adequate hemodynamics and significant dyspnea NTG 0.5-0.7 mcg/kg/min IV titrated NTE 200 mcg/min Nitroprusside 0.3 mcg/kg/min titrated q5-10min Nesiritide 2mcg/kg then 0.01 mcg/kg/min4 Pressors / Inotropes if not perfusing Milrinone 50 mcg/kg over 10min then 0.5 mcg/kg/min Dobutamine 2-20 mcg/kg/min Consider LVAD or ECMO if absolutely necessary References Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;128(16). doi:10.1161/CIR.0b013e31829e8776 &#8617; &#8617;2 &#8617;3 Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure. Journal of the American College of Cardiology. 2017;70(6):776-803. doi:[10.1016/j.jacc.2017.04.025 &#8617; Tintinalli JE, Stapczynski JS, Ma OJ, Cline D, Meckler GD, Yealy DM, eds. Tintinalli’s Emergency Medicine: A Comprehensive Study Guide. Eight edition. New York: McGraw-Hill Education; 2016. &#8617; Lexi-Drugs. Lexicomp. Wolters Kluwer Health, Inc. Riverwoods, IL. Available at: http://online.lexi.com. &#8617;",
    "tags": "",
    "url": "/peripheral_brain/diseases/chf.html"
  },{
    "title": "COPD",
    "text": "Dx1 COPD Defined as FEV1/FVC ≤ 0.7 Other respiratory SSx are cause for suspicion, but not diagnostic Screen for α-1 antitrypsin deficiency Classification All staging must be done when stable. Pts cannot be staged during an exacerbation GOLD (Spirometric) Assessment GOLD Stage Severity FEV1 Criteria 1 Mild ≥ 80% 2 Moderate [50%,80) 3 Severe [30%,50%) 4 Very Severe &lt; 30% Symptomatic Assessment mMRC Grade SSx Description 0 SOB w/ strenuous exercise 1 SOB when hurrying or going uphill 2 Stop for breath at own pace, must walk slower than other 3 Unable to walk 100m w/o SOB 4 Cannot leave house or easily dress self w/o SOB Group Assignment &ge; 2 exacerbations or &ge; 1 hospitalization C D &le; 1 exacerbation No hospitalization A B mMRC &le; 1 CAT &lt; 10 mMRC &ge; 2 CAT &ge; 10 Outpatient Tx1 Smoking Cessation Vaccination Influenza Consider PPSV23 in pts &lt; 65 with comorbidities or with FEV1 &lt; 40% Everyone gets a SABA inhaler Can add supplemental O2 as needed, target O2sat ≥ 90% Group A Bronchodilator Try different bronchodilator Group B LABA or LAMA LAMA + LABA Group C LAMA LAMA + LABA (preferred) or LABA + ICS Group D LAMA LAMA + LABA or LABA + ICS or LAMA + LABA + ICS Preferred to try LAMA + LABA then LAMA + LABA + ICS Add Roflumilast if continued exacerbations, FEV1 &lt; 50% Consider macrolide Abx in former smokers Exacerbation Tx1, 2 Classification No respiratory Failure: RR 20-30 BPM, no accessory muscle use, improves w/ supplemental O2, no increase in PaCO2, and no changes in mental status Non-life Threatening Acute Respiratory Failure: Hypercarbia 50-60, accessory muscle use, no mental status changes Life Threatening Acute Respiratory Failure: Mental status changes, hypercabia &gt; 60, acidosis Tx Give Non-invasive ventilation for respiratory compromise Add / increase bronchodilators (SABA or SABA + SABA appropriate) Consider Epinephrine 0.3-0.5mg SubQ Q20min x3 doses or Terbutaline 0.25mg SubQ Q20min x3 doses if not responding to or tolerating inhaled bronchodilators Consider GCs Prednisone 40-60mg Q4-6H or equivalent Methylprednisolone 1mg/kg IV is a good parenteral choice Usually 5-7d course Consider 5-7d of Abx Usually Azithromycin 500mg on day 1 then 250mg QD x4d3 Can consider doxycycline or Amox or Augmentin Coverage of Strep pneumoniae, H. influenzae, and Moraxella catarrhalis References Vogelmeier C, Agusti A, et al. Global Initiative for Chronic Obstructive Lung Disease. Available Here &#8617; &#8617;2 &#8617;3 Tintinalli JE, Stapczynski JS, Ma OJ, Cline D, Meckler GD, Yealy DM, eds. Tintinalli’s Emergency Medicine: A Comprehensive Study Guide. Eight edition. New York: McGraw-Hill Education; 2016. &#8617; Lexi-Drugs. Lexicomp. Wolters Kluwer Health, Inc. Riverwoods, IL. Available at: http://online.lexi.com. &#8617;",
    "tags": "",
    "url": "/peripheral_brain/diseases/copd.html"
  },{
    "title": "HLD",
    "text": "Dx1, 2 Calculation is inaccurate if LDL &lt; 70, and adjustments exist in that circumstance. Normal Labs Lab Normal Abnormal TG &lt; 150 ≥ 200 HDL   &lt; 40 (men)&lt; 50 (women) LDL &lt; 100 ≥ 160 Non-HDL &lt; 130 ≥ 190 Tx1 Statin Classification Low Medium High &lt; 30% LDL reduction 30-49&amp; LDL reduction ≥ 50% LDL reduction Simvastatin 10mg Atorvastatin 10-20mg Atorvastatin 40-80mg Pravastatin 10-20mg Rosuvastatin 5-10mg Rosuvastatin 20-40mg Lovastatin 20mg Simvastatin 20-40mg   Fluvastatin 20-40mg Pravastatin 40mg     Lovastatin 40mg     Fluvastatin 40mg BID or 80mg XL QD     Pitavastatin 1-4mg   Statin Initiation Pt has Clinical ASCVD Stratify based on risk Clinical ASCVD: ACS, Hx of MI, Stroke, TIA, PAD Major Events ACS w/i 12mo Hx of MI Hx of ischemic stroke Symptomatic PAD High-risk Conditions ≥ 65yo Familial hypercholesterolemia Prior CABG or PCI DM HTN eGFR &lt; 60 Smoker LDL ≥ 100 despite maximal statin therapy CHF Very High ASCVD Risk Multiple ASCVD events or 1 major event w/ multiple high-risk conditions High-intensity statin Add ezetimibe if LDL ≥ 70 Add PCSK9 if LDL ≥ 70 or non-LDL ≥ 100 w/ ezetimibe and statin All other risk stratification &gt; 75 yo: Consider moderate or high-intensity statin as tolerated ≤ 75 yo: High intensity statin, followed by ezetimibe if LDL-C ≥ 70 All DM pts 40-75yo receive moderate intensity, if not higher All pts 20-75yo w/ LDL ≥ 190 receive high-intensity ASCVD Risk ≥ 7.5% w/ other risk factor or ≥ 20% get high intensity statin All pts 40-75 w/ LDL 70-189 receive intermediate statin Use lower intensity statins if high-intensity not tolerated Statin Adjustment NLA Risk Stratification Low 0-1 major ASCVD risk factors Moderate 2 major ASCVD risk factors High ≥ 3 major ASCVD risk factors DM CKD 3B or 4 LDL ≥ 190 ≥ 15% ASCVD 10-Year Risk Very High ASCVD DM w/ ≥ 2 other risk factors or end organ damage Major Risk Factor M ≥ 45yo or F ≥ 55yo FHx of Early CHD &lt; 55yo for M relatives &lt; 65yo for F relatives Current Smoker BP ≥ 140/90 or currently on BP meds HDL &lt; 40 (M) or &lt; 50 (F) Treatment Goals Risk Category Non-HDL LDL Apo B Low &lt; 130 &lt; 100 &lt; 90 Moderate &lt; 130 &lt; 100 &lt; 90 High &lt; 130 &lt; 100 &lt; 90 Very High &lt; 130 &lt; 70 &lt; 80 See NLA Part 2 for Special Population Management (Jentzer 2015)3 Misc Drug Therapies Drug ΔLDL ΔNon-HDL ΔHDL ΔTG BAS ↓ 15-30% ↓ 4-16% ↑ 3-5% ↑ 0-10% Nicotinic Acid ↓ 5-25% ↓ 8-23% ↑ 15-35% ↓ 20-50% Fibrates ↓ 5- ↑ 20% ↓ 5-19% ↑ 10-20% ↓ 20-50% Omega-3s ↓ 6-↑ 25% ↓ 5-↑ 14% ↓ 5-↑ 7% ↓ 19-44% Cholesterol Absorption Inhibitors ↓ 13-20% ↓ 14-19% ↑ 3-5% ↓ 5-11% Do not use fibrates with statins References Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. Journal of the American College of Cardiology. November 2018. doi:10.1016/j.jacc.2018.11.003 &#8617; &#8617;2 Jacobson TA, Ito MK, Maki KC, et al. National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1—Full Report. Journal of Clinical Lipidology. 2015;9(2):129-169. doi:10.1016/j.jacl.2015.02.003 &#8617; Jentzer JC, Coons JC, Link CB, Schmidhofer M. Pharmacotherapy Update on the Use of Vasopressors and Inotropes in the Intensive Care Unit. Journal of Cardiovascular Pharmacology and Therapeutics. 2015;20(3):249-260. doi:10.1177/1074248414559838 &#8617;",
    "tags": "",
    "url": "/peripheral_brain/diseases/hld.html"
  },{
    "title": "HTN",
    "text": "Dx1 Tx HTN Crisis1, 2 Dx graph TD; start[SBP &gt; 180orDBP &gt; 120] --&gt; uore{End-OrganDamage}; uore --&gt;|Yes| emerg[Emergency]; uore --&gt;|No| urg(Restart/intensify PO Therapy and F/U); emerg --&gt; icu(ICU Admit); icu --&gt; cond{Aortic DissectionPheochromocytomaPre-/Eclampsia}; cond --&gt;|Yes| ycond(InitiateCondition-SpecificTherapies); cond --&gt;|No| ncond(IV TherapiesDrop by 25% in 1st hrTarget 160/110 in 2-6hrTarget Normal 24-48hr later); Tx References Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Journal of the American College of Cardiology. 2018;71(19):e127-e248. doi:10.1016/j.jacc.2017.11.006 &#8617; &#8617;2 Benken ST. ACCP Hypertensive Emergencies. 2018. Available at: https://www.accp.com/docs/bookstore/ccsap/ccsap2018b1_sample.pdf &#8617;",
    "tags": "",
    "url": "/peripheral_brain/diseases/htn.html"
  },{
    "title": "Stress Ulcer Prophylaxis",
    "text": "Tx Some evidence benefits of SUP do not outweigh risks1 Treatment with PPIs, H2RAs, or Sucralafate is generally consider equivalent and is chosen based upon institutional preference and convenience, along with individual pt considerations1 ASHP recommends initiating with ≥ 1 major risk factor or ≥ 2 minor risk factors Indications2 Major Risk Factors Minor Risk Factors Coagulopathy (INR &gt; 1.5, Pmts &lt; 50k, or aPTT &gt; 2x ULN) Sepsis Expected Mechanical Ventilation ≥ 48hr ICU &gt; 7d Hx of GI ulceration / bleeding w/i 1yr Occult bleeding ≥ 6d GCS ≤ 10 GCs &gt; 250mg hydrocortisone equivalent Burns &gt; 35% BSA   Partial Hepatectomy   Multiple Trauma   Hepatic Failure   Spinal Cord Injuries   Initial Dosing2 Drug Normal Renal Fx Impaired Renal Fx Cimetidine 300mg PO/IV QID50mg/hr IV &lt; 30: 300mg BID or 25 mg/hr Famotidine 20mg PO/IV BID1.7mg/hr IV &lt; 30: 20mg QD or 0.85 mg/hr Ranitidine 150mg PO BID50mg IV Q4-6H6.25mg/hr IV &lt; 50: 150mg PO QD-BID, 50mg IV Q12-24H, or 2-4mg/hr Omeprazole 40mg load then 20-40mg QD No adjustment Sucralfate 1g QID No adjustment References Barletta JF, Bruno JJ, Buckley MS, Cook DJ. Stress Ulcer Prophylaxis: Critical Care Medicine. 2016;44(7):1395-1405. doi:10.1097/CCM.0000000000001872 &#8617; &#8617;2 Erstad BL, et al. ASHP Therapeutic Guidelines on Stress Ulcer Prophylaxis. 1999. &#8617; &#8617;2",
    "tags": "",
    "url": "/peripheral_brain/diseases/stressUlcerProphylaxis.html"
  },{
    "title": "VTE",
    "text": "Dx DVT: Well’s Score PE: PERC Rule DVT Prophylaxis1 Padua Score is somewhat useful in risk stratification Caprini Score for surgical pts Low Risk: Consider ICD or no therapy High bleeding risk: ICD over no therapy Otherwise: LMWH or UFH (low dose) Parenteral Dosing2 Drug Dose Adjustments Notes UFH 5000 Units Q8-12H None Higher risk of HIT Enoxaparin 40mg SubQ QD30mg SubQ BID CrCl &lt; 30: 30mg SubQ QD Low risk of HIT Fondaparinux 2.5mg SubQ QD CrCl 30-50: CautionCrCl &lt; 30: CI Must be ≥ 50kg PO Dosing2 Drug Indication Dosing Adjustments Notes Rivaroxiban THA or TKA 10mg QD x10-14d NTE 34d starting 6-10hr after surgery CrCl 30-50: CautionCrCl &lt; 30: CI Use longer interval for THA, shorter end for TKA Apixaban THA or TKA 2.5mg BID x10-14d NTE 34d starting 12-24hr after surgery CrCl &lt; 30: No evidence   Dabigatran THA 110mg x1 dose 1-4hr after surgery OR 220mg on the first day, then 220mg QD 10-14d NTE 35d CrCl 30-50: Consider 150mg QD instead of 220mgCrCl &lt; 30: No evidence Times close to 30d recommendedWatch w/ PGP inhibitors DVT Tx3 At least 3mo anticoag PO therapy (DOAC or warfarin) preferred if no cancer LMWH preferred if cancer Generally stick to 3, low-moderate bleed risk unprovoked VTE recommend extended (no scheduled stop date) If DVT recurs while on anticoag, switch to LMWH or increase LMWH by 25-33% if already on LMWH ASA is not as good as anticoag, but better than nothing Distal DVT w/ serial imaging can forgo anticoag if thrombus does not extend PE Tx3 Low Risk: Tx outpatient Thrombolysis for hemodynamic instability (SBP &lt; 90) w/o high bleed risk Give thrombolytics if pt deteriorates after anticoag if low bleed risk Systemic over catheter directed Can be used in stable PE when risks outweigh benefits, but off label and not usually recommended Hemodynamically unstable / shock, high bleed risk, or failure of systemic thrombolysis =&gt; catheter directed removal No thrombolysis if hemodynamically stable DVT/PE Tx Dosing Initial Parenteral Anticoag2 Drug Dose Adjustments UFH 80 U/kg IVB then 18 U/kg/hr333 U/kg SubQ then 250 U/kg Q12H Monitor aPTT Q4-6H (titration) or Q24H (Wt based) based on protocolGoal 1.5-2x ULN Enoxaparin 1 mg/kg SubQ Q12H1.5 mg/kg SubQ Q24H CrCl &lt; 30: 1 mg/kg SubQ Q24H Fondaparinux &lt; 50kg: 5mg SubQ QD50-100kg: 7.5mg SubQ QD&gt; 100kg: 10mg SubQ QDx5-9d CrCl 30-50: CautionCrCl &lt; 30: CI PO Anticoag2 Drug Dose Notes Warfarin 2.5-7.5mg PO QD initial Start w/ parenteral anticoag until therapeutic INRTitrate based on INR (Goal 2-3) Rivaroxaban 15mg PO BID x21d then 20mg PO QD Must be taken w/ foodNo initial parenteral anticoag needed Apixaban 10mg PO BID x7d then 5mg PO QD No initial parenteral anticoag needed Dabigatran 150mg PO BID Initiate after 5d of parenteral anticoagulantAvoid if CrCl ≤ 30 (never in trials)Watch w/ PGP inhibitors Edoxaban &gt; 60kg: 60mg PO QD≤ 60kg: 30mg PO QD Initiate after 5d of parenteral anticoagulantDo not use if CrCl &gt; 95 or &lt; 15CrCl 15-50: 30mg QD Thrombolytics Thrombolytic Dosing2 Drug Dose Notes Alteplase 100mg IV over 2hr Check for CIs (below)Start heparin near end of infusion or when aPTT is 2x ULN Tenecteplase (off-label) Wt based bolus over 5 seconds (See table below) Check for CIs (below) Tenecteplase Dosing2 Wt (kg) Dose &lt; 60kg 30mg [60,70) 35mg [70,80) 40mg [80,90) 45mg ≥ 90 50mg CIs3 Major CIs Structural intracranial disease Previous intracranial hemorrhage Ischemic stroke within 3 mo Active bleeding Recent brain or spinal surgery Recent head trauma with fracture or brain injury Bleeding diathesis Relative CIs Systolic BP &gt;180 Diastolic BP &gt;110 Recent bleeding (non-intracranial) Recent surgery / invasive procedure Ischemic stroke more than 3 mo previously Anticoagulated (eg, VKA therapy) Traumatic CPR Pericarditis or pericardial fluid Diabetic retinopathy Pregnancy Age &gt;75yr Low body weight (eg &lt; 60 kg) Female Black race Preferred Agents Preferred Anticoagulants3 Factor Agent Cancer LMWH Parenteral Therapy CI Rivaroxaban or Apixaban(others require bridge) QD PO Therapy Preferred Rivaroxaban, Edoxaban, Warfarin Liver disease / coagulopathy LMWH CrCl &lt; 30 Warfarin CAD Warfarin, Rivaroxaban, Apixaban, Edoxaban Hx of GI Bleeds Apixaban, Warfarin Thrombolytic Use UFH Infusion Pregnancy LMWH References Gould MK, Garcia DA, Wren SM, et al. Prevention of VTE in Nonorthopedic Surgical Patients. Chest. 2012;141(2):e227S-e277S. doi:10.1378/chest.11-2297 &#8617; Lexi-Drugs. Lexicomp. Wolters Kluwer Health, Inc. Riverwoods, IL. Available at: http://online.lexi.com. &#8617; &#8617;2 &#8617;3 &#8617;4 &#8617;5 &#8617;6 Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease. Chest. 2016;149(2):315-352. doi:10.1016/j.chest.2015.11.026 &#8617; &#8617;2 &#8617;3 &#8617;4",
    "tags": "",
    "url": "/peripheral_brain/diseases/vte.html"
  },{
    "title": "Clinical PK",
    "text": "Formulas 1 General PK 1-Compartment Model Vancomycin 1, 2, 3, 4 Peak: 20-40 mg/L Trough: 10-15 mg/L (minor infections) or 15-20 mg/L (serious infections or lung penetration) Loading Dose: 25-30 mg/kg (Wt) NTE 15 mg/min k ≈ 0.00083 × CrCl + 0.0044 Vd ≈ 0.4-1 L/kg, usually 0.6-0.7 L/kg for appropriate effect to prevent toxicity Initial Vanc Dosing Calculator Level-Based Vanc Dosing Calculator Aminoglycosides 1, 5 See also: Stanford Aminoglycoside Dosing Guidelines k ≈ 0.00293 × CrCl + 0.014 Vd ≈ 0.26 L/kg × Wt Vd may be closer to 0.3-0.35 L/kg in critically ill pts due to fluid overload Use ABW if Wt/IBW &gt; 130% Traditional Dosing Gentamicin / Tobramycin Target Levels 1, 6 Infection Target Peak (mcg/mL) Target Trough (mcg/mL) General 4-10 le; 1 UTI &lt; 5 ≤ 1 Bacteremia &gt; 5 ≤ 1 Pneumonia &gt; 6 ≤ 1 Endocarditis from P. aeruginosa &gt; 12 ≤ 1 Amikacin Target Levels 1, 6 Infection Target Peak (mcg/mL) Target Trough (mcg/mL) General 15-30 4-10 UTI &gt; 15 4-10 Bacteremia &gt; 20 4-10 Pneumonia /Serious Infections &gt; 24 4-10 Target Cpk / MIC &gt; 10 for efficacy Draw levels 1hr after infusion ends Consider target troughs of ≤ 1.5-2 (tob/gent) or ≤ 10 (amikacin) for life-threatening infections. Look up specific trough/peak targets for given infection site. Initial Aminoglycoside Dosing Calculator Extended-Interval Dosing Load with 7 mg/kg (15 mg/kg Amikacin) Determine initial dosing frequency from table below Draw level at 6-14hr after 1st or 2nd dose Plot level on Hartford Nomogram (divide level by 2 for Amikacin) If doses other than those above are used, multiplying the level by (expected)/(given) dose can help adjust properly for the nomogram, although this has less evidence Adjust interval per nomogram If borderline, go with longer interval Hartford Nomogram Initial Aminoglycoside Interval CrCl Interval ≥ 60 Q24H 40-59 Q36H 20-39 Q48H &lt; 20 Monitor Serial Conc. &amp; Admin when &lt; 1 mcg/mL References DiPiro JT, ed. Pharmacotherapy: A Pathophysiologic Approach. Tenth edition. New York: McGraw-Hill Education; 2017. &#8617; &#8617;2 &#8617;3 &#8617;4 &#8617;5 Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. American Journal of Health-System Pharmacy. 2009;66(1):82-98. doi:10.2146/ajhp080434 &#8617; Matzke GR, McGory RW, Halstenson CE, Keane WF. Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrobial Agents and Chemotherapy. 1984;25(4):433-437. doi:10.1128/AAC.25.4.433 &#8617; Deryke CA, Alexander DP. Optimizing Vancomycin Dosing through Pharmacodynamic Assessment Targeting Area under the Concentration-Time Curve/Minimum Inhibitory Concentration. Hospital Pharmacy. 2009;44(9):751-765. doi:10.1310/hpj4409-751] &#8617; Nicolau DP, Freeman CD, Belliveau PP, Nightingale CH, Ross JW, Quintiliani R. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrobial Agents and Chemotherapy. 1995;39(3):650-655. doi:10.1128/AAC.39.3.650 &#8617; Lexi-Drugs. Lexicomp. Wolters Kluwer Health, Inc. Riverwoods, IL. Available at: http://online.lexi.com. &#8617; &#8617;2",
    "tags": "",
    "url": "/peripheral_brain/drugClasses/clinicalPk.html"
  },{
    "title": "Vasopressors",
    "text": "Vasopressors Vasopressor Dosing1 Drug Initial Dose Typical Dose Titration q5-15min Weaning q5-15min Epinephrine 0.02-0.05 mcg/kg/min 0.005-0.2 mcg/kg/min 0.02-0.05 mcg/kg/min 0.02-0.05 mcg/kg/min Norepinephrine 0.01-0.04 mcg/kg/min 0.04-1 mcg/kg/min 0.02-0.04 mcg/kg/min 0.02-0.04 mcg/kg/min Dopamine 5-10 (inotropic)&gt; 10 mcg/kg/min (inopressor) 2-20 mcg/kg/min 2-5 mcg/kg/min 1 mcg/kg/min Phenylephrine 0.1-0.3 mcg/kg/min 0.1-1.5 mcg/kg/min 0.2-0.4 mcg/kg/min 0.2-0.4 mcg/kg/min Vasopressin 0.01-0.04 U/min 0.01-0.04 U/min No titration No weaning Dobutamine 2.5-5 mcg/kg/min 2.5-10 mcg/kg/min 2.5-5 mcg/kg/minAlter based on CO/CI or SVO2 2.5-5 mcg/kg/min Milrinone 0.25 mcg/kg/min 0.25-0.75 mcg/kg/min Alter based on CO/CI or SVO2 No weaning Vasopressor Classification2 Drug Classification Note Epinephrine Inopressor Can bump lactate d/t β stimulation Norepinephrine Inopressor Good 1st line choice in almost all situations Dopamine Inopressor Increased mortality in comparison to NE Phenylephrine Vasopressor   Vasopressin Vasopressor No pulmonary constriction Dobutamine Inodilator Increased myocardial O2 demand d/t chronotropy Milrinone Inodilator Long t1/2 removing need for weaning Vasopressor Hemodynamic Effects2 Drug HR Inotropy Vasoconstriction Vasodilation Dopaminergic Epinephrine ++++ ++++ ++++ +++ 0 Norepinephrine + ++ ++++ 0 0 Dopamine (Inotropy)Dopamine (Inopressor) +++ +++ - +++ 0++ - +++ +0 ++++++ Phenylephrine 0 0 +++ 0 0 Vasopressin 0 0 ++++ 0 0 Dobutamine ++ +++ - ++++ 0 ++ 0 Milrinone + +++ 0 ++ 0 Vasopressor Receptor Specificity3 Drug α-1 β-1 β-2 Other Epinephrine +++++ ++++ +++ - Norepinephrine +++++ +++ ++ - Dopamine +++ ++++ ++ DA Phenylephrine +++++ 0 0 - Vasopressin 0 0 0 V1 (vasoconstriction)V2 (renal tubules) Dobutamine + +++++ +++ - Milrinone 0 0 0 PDE-3 Push-Dose EPI 4 Mixing 9mL NS in 10mL syringe Add 1 mL (100mcg) cardiac epinephrine (0.1mg/mL) Caution: above is for 1mg/10mL (0.1mg/mL) premix syringes, EPI vials are 1mg/1mL Resulting solution is 100mcg/10mL (10mcg/mL) Epinephrine Admin 0.5-2mL (5-20 mcg) Q2-5min PRN of above solution Doses last ≈ 10min If mixing not possible, give 0.5mL dose of pure cardiac epi (50mcg) DO NOT ADMINISTER 1mg EPI TO INDIVIDUALS NOT IN CARDIAC ARREST References Jentzer JC, Coons JC, Link CB, Schmidhofer M. Pharmacotherapy Update on the Use of Vasopressors and Inotropes in the Intensive Care Unit. Journal of Cardiovascular Pharmacology and Therapeutics. 2015;20(3):249-260. doi:10.1177/1074248414559838 &#8617; Hollenberg SM. Vasoactive Drugs in Circulatory Shock. American Journal of Respiratory and Critical Care Medicine. 2011;183(7):847-855. doi:10.1164/rccm.201006-0972CI &#8617; &#8617;2 Overgaard CB, Džavík V. Inotropes and Vasopressors: Review of Physiology and Clinical Use in Cardiovascular Disease. Circulation. 2008;118(10):1047-1056. doi:10.1161/CIRCULATIONAHA.107.728840 &#8617; Weingart S. Push-dose pressors for immediate blood pressure control. Clinical and Experimental Emergency Medicine. 2015;2(2):131-132. doi:10.15441/ceem.15.010 &#8617;",
    "tags": "",
    "url": "/peripheral_brain/drugClasses/pressors.html"
  }]};
